referring to fig1 , pc - 12 cells were plated on inhibitory myelin substrates ( 0 ). unmodified c3 added to the tissue culture medium at concentration from 0 . 00025 - 50 ug / ml did not significantly improve neurite outgrowth over the untreated control ( grey bars ). c3 was only effective in stimulating neurite outgrowth for cells plated on myelin substrates after scrape - loading ( black bars ). this figure demonstrates the limited or no penetration in cells when passively added to the tissue culture medium . please see example 4 below for techniques . referring to fig2 , this figure provides a demonstration that c3aplt and c3aps , adp ribosylate rho . western blot showing rhoa in untreated cells ( lane 1 ), and cells treated with c3aplt ( lane 2 ) or c3aps ( lane 3 ). when rho is adp ribosylated by c3 it undergoes a molecular weight shift ( lehmann et al supra ), as observed for lanes 2 and 3 . please see example 4 below for techniques . referring to fig3 , this figure shows intracellular activity after treatment with c3aplt . detection that the new fusion c3 penetrates into the cells . immunocytochemistry with anti - c3 antibody of pc - 12 cells plated on myelin and treated with c3 ( a ) or c3aplt ( 13 ). cells in a ( fig3 a ) are not immunoreactive because c3 has not penetrated into the cells . cells in b ( fig3 b ) are immunoreactive and they are able to extend neurites on myelin substrates . please see example 4 below for techniques . turning to fig4 , this figure shows that c3 - antennapedia fusion proteins promote growth on inhibitory substrates . the percent of neurons that grow neurites was counted for each treatment . the dose response experiment shows that c3aplt and c3aps promote more neurite growth per cell than control pc - 12 cells plated on myelin ( 0 ). pc - 12 cells were plated on myelin and either scrape loaded with unmodified c3 ( c3 50 ) left untreated ( 0 ) or treated with various concentrations of c3aplt . compared to c3 used at 25 ug / ml , c3aps is effective at stimulating more cells to grow neurites at 0 . 0025 ug / ml , a dose 10 , 000 x less . please see example 4 below for techniques . fig5 shows a dose - response experiment showing that c3aplt and c3aps elicit long neurites to grow when cells are plated on inhibitory substrates . the length of neurites was measured for each treatment . pc - 12 cells were plated on myelin and either scrape loaded with unmodified c3 ( c3 50 ) left untreated ( 0 ) or treated with various concentrations of c3aplt . compared to c3 used at 25 ug / ml , c3aps is effective at stimulating more cells to longer neurite growth at 0 . 0025 ug / ml , a dose 10 , 000 . times . less . please see example 4 below for techniques . as may be seen fig6 shows primary neurons growing on inhibitory substrates after treatment with c3aplt . rat retinal ganglion cells were plated on myelin substrates and treated with different concentrations of c3aplt . concentrations of 0 . 025 and above promoted significantly longer neurites . this dose is 1000 . times . lower than that of c3 needed to promote growth on myelin . referring to fig7 , this figure shows behavioral recovery after treatment of adult mice with c3aplt in a dose - response experiment . mice received a dorsal hemisection of the spinal cord and were left untreated ( transection ), were treated with fibrin alone ( fibrin ) or were treated with fibrin plus c3aplt at the indicated concentrations given in ug / mouse . each point represents one animal . the bbb score ( see example 6 for details ) was assessed 24 hours after treatment . animals treated with c3aplt exhibited a significant improvement in behavioral recovery compared to untreated animals . the effective dose of 0 . 5 μg is 100 . times . less than unmodified c3 used ( see previous experiment shown in canadian patent application 2 , 325 , 842 ). please see example 6 . referring to fig8 , this figure shows promotion of axon growth by c3 - tat chimeric proteins . the dose - response experiment shows that c3 - ts and c3 - tl promote more neurite growth per cell than control pc - 12 cells plated on myelin . pc - 12 cells were plated on myelin and either scrape loaded with unmodified c3 ( scrape load ) left untreated ( myelin ) or treated with various concentrations of c3 - ts ( grey bars ) or c3 - tl ( black bars ). compared to c3 used at 25 ug / ml , c3 - tl is effective at stimulating more cells to grow neurites at 0 . 0025 ug / ml , a dose 10 , 000 . times . less than c3 . referring to fig9 a and 9b , these figures show axon regeneration in injured spinal cord , i . e . anatomical regeneration after treatment with c3aplt . section of the spinal cord after anterograde labeling with horseradish peroxidase conjugated to wheat germ agglutinin ( wga - hrp ). a ) sprouting of cut axons into the dorsal white , matter . arrows show regenerating axons distal to the lesion . b ) same section 3 mm from the lesion site . arrows show regenerating axons . referring to fig1 , this figure shows that c3 - aplt protected neurons from cell death following spinal cord injury . apoptotic ( dying ) cells were counted following tunel labeling ( see example 16 ) 2 mm rostral to the lesion ( rostral ) at the lesion site ( lesion ) and 2 mm caudal to the lesion site ( caudal ). bars show average counts of tunel positive cells from 4 animals treated with fibrin only after spinal cord injury as control ( white bars ), or with c3aplt in fibrin at 1 μg ( black bars ). treatment with c3aplt show significantly reduced numbers of tunel - labeled cells ( dying cells ). non - injured spinal cord samples were also processed and these spinal cords did not show tunel labeling , as expected . referring to fig1 , this figure shows that c3aplt and c3basic3 promote rapid neurite outgrowth compared to untreated cells when cells are plated on plastic as part of a rapid bioassay ( see example 4 ). referring to fig1 a and 12b , to further support the ability of c3 - like chimeric proteins to promote neurite outgrowth on inhibitory substrates , we examined the response of primary cultures plated on inhibitory substrates to c3aplt treatment . purified retinal ganglion cells ( rgcs ) were plated on myelin , or cspg substrates and treated with varying concentrations of c3aplt . during the rgc dissection great care was taken in order to try to limit the amount of mechanical manipulation of the cells , however , the isolation protocol requires that some triturating take place in order to dissociate and separate the cells . when rgcs are plated on inhibitory substrates , they maintained a similar round appearance to pc - 12 cells plated on myelin . treatment of rgcs with c3aplt promoted neurite outgrowth and increased neurite length on both myelin and cspg substrates . in contrast to the wide range of concentrations shown to be effective in other pc - 12 experiments a narrower range of c3aplt treatment , 0 . 025 ug / ml to 50 ug / ml promoted neurite outgrowth and increased neurite length on myelin . in the case of rgcs plated on cspg substrates , effective concentration ranges of 0 . 0025 ug / ml to 50 ug / ml were observed . referring to fig1 , a fusion protein of this invention , c3aplt , can inhibit neovascularization represented by tube formation in an in vitro model comprising huvec endothelial cells in culture . in the absence of the fusion protein , extensive tube formation by huvec endothelial cells is observed ( fig1 a , area 30 ) when the cells are cultured in a matrigel ™ matrix ( bd biosciences ). this assay is a cell culture assay for antiogenesis . tube formation in vitro can be a model for angiogenesis and neovascularization in vivo . however , in the presence of a fusion protein of this invention ( e . g ., c3aplt as seq id 43 was administered to the cell culture in this example ), a substantial reduction in the number and density of tubes formed by huvec endothelial cells when the cells are cultured in a matrigel ™ matrix is observed ( fig1 b , area 31 ), demonstrating an inhibition of angiogenesis by the fusion protein . reduction in tube formation can indicate inhibition of angiogenesis . neovascularization in retinal diseases such as macular degeneration , retinitis pigmentosa , stargardt &# 39 ; s disease , diabetic retinopathy , hypertensive retinopathy , and occlusive retinopathy , can be reduced or eliminated by inhibition of angiogenesis comprising administration of a fusion protein of this invention to the eye of a patient . administration of a fusion protein of this invention can be useful to treat such diseases . thus , in one aspect , this invention comprises a method of treatment of a disease of the eye selected from the group consisting of macular degeneration , retinitis pigrnentosa , stargardt &# 39 ; s disease , diabetic retinopathy , hypertensive retinopathy , and occlusive retinopathy , the method comprising administration to a patient in need of such treatment a therapeutically effective amount of a pharmaceutical composition comprising : a ) a polypeptide comprising an amino acid sequence of a transport agent covalently linked to an amino acid sequence of an active agent , said amino acid sequence of said active agent consisting of adp - ribosyl transferase c3 or a fragment thereof retaining an adp - ribosyl transferase activity , said amino acid sequence of said transport agent facilitating uptake of the active agent by a receptor - independent mechanism and being selected from the group consisting of a subdomain of hiv tat protein , a homeodomain of antennapedia , and a histidine tag , said polypeptide having adp - ribosyl transferase activity , and ; b ) a pharmaceutically acceptable carrier . in another aspect , this invention comprises a method of inhibiting or substantially reducing the rate of subretinal neovascularization and proliferation of neovascular tissue in the eye of a mammalian host comprising administration to said host a therapeutically effective amount of a pharmaceutical composition comprising : a ) a ) a polypeptide comprising an amino acid sequence of a transport agent covalently linked to an amino acid sequence of an active agent , said amino acid sequence of said active agent consisting of adp - ribosyl transferase c3 or a fragment thereof retaining an adp - ribosyl transferase activity , said amino acid sequence of said transport agent facilitating uptake of the active agent by a receptor - independent mechanism and being selected from the group consisting of a subdomain of hiv tat protein , a homeodomain of antennapedia , and a histidine tag , said polypeptide having adp - ribosyl transferase activity , and ; b ) a pharmaceutically acceptable carrier . referring to fig1 , the intentional inactivity of a mutant of the c3 - 07 fusion protein , i . e ., inactive c3 - 07q189a , as assayed by a bioassay with ng - 108 cells is illustrated . ng - 108 cells cultured with an active fusion protein of this invention , c3 - 07 , exhibit accelerated neurite outgrowth , which neurite outgrowth is the result of the presence of c3 - 07 . however , neurite outgrowth of cells treated with intentionally inactive mutant c3 - 07a189a is similar to that of the control cells which are not treated with additional protein . the similarity to the control group demonstrates that the intentionally inactive mutant protein c3 - 07q189a is inactive with respect to stimulation of neurite outgrowth . refering to fig1 , an injection of a fusion protein of this invention , c3 - 07 , can prevent ( substantially reduce the observed rate of ) death of retinal ganglion cells ( rgcs ) induced by crush of the optic nerve following a single injection . after axotomy or axotomy with injection of vehicle ( phosphate buffered saline ) cells die after axotomy of the optic nerve . when c3 - 07q189a , an intentionally inactive mutant of c3 - 07 , is injected into the eye it is not able to prevent death of the rgcs . a single injection of c3 - 07 prevents cell death and the number of surviving cells is similar to that in control , non - axotomized retinas . the results demonstrate that c3 - 07 as a fusion protein of this invention can prevent death of retinal neurons ; the neuroprotective activity of c3 - 07 requires that the enzymatic activity of the c3 fusion protein is retained . c3 - 07 exhibits adp - ribosylation activity , whereas c3 - 07q189a is intentionally inactive with respect to adp - ribosylation activity . administration of a pharmaceutical composition comprising a fusion protein of this invention to a patient in need of treatment for a disease of the eye selected from the group consisting of macular degeneration , retinitis pigmentosa , stargardt &# 39 ; s disease , diabetic retinopathy , hypertensive retinopathy , and occlusive retinopathy can substantially reduce or prevent angiogenesis associated with subretinal neovascularization , choroid neovascularization underlying the macula , and a proliferation of neovascular tissue in the subretinal choroid proximal to the macula in an eye in a mammalian host and comprises a method of treatment of a disease of the eye selected from the group consisting of macular degeneration , retinitis pigmentosa , stargardt &# 39 ; s disease , diabetic retinopathy , hypertensive retinopathy , and occlusive retinopathy . in one aspect , the compositions of this invention are useful for inhibiting or substantially reducing the rate of subretinal neovascularization and proliferation of neovascular tissue related to a disease of the eye selected from the group consisting of macular degeneration , retinitis pigmentosa , stargardt &# 39 ; s disease , diabetic retinopathy , hypertensive retinopathy , and occlusive retinopathy . the method can be useful as a prophylactic treatment to prevent further onset or progression of macular degeneration in an eye that exhibits symptoms of a disease of the eye selected from the group consisting of macular degeneration , retinitis pigmentosa , stargardt &# 39 ; s disease , diabetic retinopathy , hypertensive retinopathy , and occlusive retinopathy . in another aspect , the method can be useful as a prophylactic treatment to prevent the deposition of drusen and the death of cells in the macula . in another aspect , the method can prevent the death of photoreceptor cells ( which photoreceptor cells are also herein referred to as photoreceptors ) in the eye of a patient by acting on intracellular mechanisms of the regulation of cell death . the method can also be useful to prevent onset or progression of macular degeneration in an eye that does not exhibit vision - obscuring symptoms of macular degeneration , especially in an eye of a patient whose other eye does exhibit vision - obscuring symptoms of macular degeneration . in another aspect of this invention , a method of treatment of a disease of the eye selected from the group consisting of macular degeneration , retinitis pigmentosa , stargardt &# 39 ; s disease , diabetic retinopathy , hypertensive retinopathy , and occlusive retinopathy comprises administration such as by injection or implantation into tissue proximal to the eye of a therapeutically effective amount of a polypeptide of this invention , or of a sterile pharmaceutical composition of this invention suitable for injectable administration and comprising a polypeptide of this invention and a carrier suitable for injectable use ( e . g ., sterile , sterilizable , and isotonic with blood ), which polypeptide or pharmaceutical composition can prevent or delay the onset of angiogenesis associated with the group consisting of subretinal neovascularization , choroid neovascularization underlying the macula , and a proliferation of neovascular tissue in the subretinal choroid proximal to the macula in an eye of an average patient in a statistically relevant population of patients to produce a mean delay in the onset of vision loss that can result from said angiogenesis , the mean delay of onset being measured relative to the mean time of onset of vision loss that occurs in an average patient in the statistically relevant population of patients in the absence of said amount of polypeptide , the mean delay in the onset of vision loss comprising a period of at least 1 month , and more preferably a period of at least 6 months , and most preferably a period of greater than 6 months . inhibition of angiogenesis by a pharmaceutical composition comprising a fusion protein of this invention such as c3aplt can be evaluated in an in vitro system that can also be useful for the study of angiogenesis in the growth of a tumor , i . e ., a system comprising cultivation of endothelial cells in the presence of an extract of basement membrane ( matrigel ™) as a model for angiogenesis and for neovascularization and proliferation of neovascular tissue in the eye of a mammal . in the experimental observation conditions , capillary - like structures or tubules associated with angiogenesis or blood vessel capillary formation can be viewed under a microscope . the inhibitory effect of a fusion protein of this invention such as c3aplt on the progress of angiogenesis or on the formation of a tubular capillary network or on the disruption of the process or progress of tumor - associated angiogenesis can be observed by following the disappearance of tubular structures in a matrigel assay . matrigel ™ matrix ( bd biosciences ) is a solubulized basement membrane preparation extracted from ehs mouse sarcoma , a tumor rich in ecm proteins . its major components are laminin , collagen iv , heparan sulfate proteoglycans , and entactin . at room temperature , bd matrigel ™ matrix polymerizes to produce biologically active matrix material which can mimic mammalian cellular basement membrane , wherein cells can behave in vitro in a manner similar to in vivo conditions . matrigel ™ matrix can provide a physiologically relevant environment for studies of cell morphology , biochemical function , migration or invasion , and gene expression . in a matrigel assay , matrigel ( about 12 . 5 mg / ml ) is thawed at about 4 ° c . the matrix ( about 50 microliters ( ul )) is added to each well of a 96 well plate and allowed to solidify for about 10 min at about 37 ° c . the wells containing solid matrigel are incubated for about 30 minutes with human umbilical vein endothelial cells ( huvec cells ) at a concentration of about 15 , 000 cells per well . when the cells are adhered , medium is removed and replaced by fresh medium supplemented with a fusion protein of this invention such as c3aplt and incubated at 37 ° c . for about 6 to about 8 hours . control wells are incubated with medium alone . to analyze the growth , tube formation can be visualized by microscopy at , for example , about 50 × magnification . the relative mean length , yx , of an angiogenesis - derived capillary network observed in an evaluation of a pharmaceutical composition comprising a fusion protein , x , of this invention can be quantified using northern eclipse software according to the instructions . data from a typical matrigel assay experiment , for example relating to the effect of a pharmaceutical composition comprising a fusion protein designated as c3aplt on length of an angiogenesis - derived capillary network are summarized in table 3 . these data show that the network formation was inhibited by approximately 13 % to about 20 % under the dose and formulation conditions used versus the inhibition produced by a control vehicle wherein zero inhibition provides 100 % growth . this effect on angiogenesis can be enhanced by using higher doses of fusion protein and by preincubation of the huvec cells with fusion protein c3aplt prior to addition of the cells to matrigel . the anti - angiogenesis effect of a composition comprising a polypeptide of this invention comprising an amino acid sequence of a transport agent covalently linked to an amino acid sequence of an active agent , wherein the amino acid sequence of the active agent retains an adp - ribosyl transferase activity can be useful for inhibiting or substantially reducing the rate of subretinal neovascularization and proliferation of neovascular tissue in the eye of a mammalian host when the composition is administered to the mammal according to the methods of this invention . it is an advantage that the current invention provides compositions comprising a fusion protein of this invention , which fusion protein after administration to a mammal , preferably proximal to the eye or into a blood vessel that provides blood to the eye , has the ability to penetrate endothelial cells in the eye that in the absence of the fusion protein can form new blood vessels . thus , when administered to the eye of a mammal , the compositions of this invention can inhibit or substantially reduce the rate of subretinal neovascularization and proliferation of neovascular tissue in the eye of the mammal . [ heading - 0370 ] description of how to measure effect on cell death in vivo one system to examine the neuroprotective effect of fusion proteins in the eye is a model of optic nerve axotomy . in the visual system , retinal ganglion cells die after optic nerve injury , and the severity and rate of cell death depends on the proximity of axonal injury to the eye . in rats , transection of the optic nerve close to the eye causes a delayed rgc death , with cells beginning to die approximately 4 days after axotomy . it has been well demonstrated that intervention with factors that prevent cell death give partial and transient rescue of cells . intraocular injection of growth factors that include bdnf , nt4 , gdnf , cntf and fgf can rescue rgcs from axotomy - induced cell dedath . other ways to rescue cells are to interfere with enzymes that contribute to apoptotic cell death . lens injury that induces macrophage activation and injection of zymosan from yeast cell walls promote survival of rgcs . to study the inactivation of rho on rgc survival c3 - 07 was injected intot he vitreous after axotomy . to separate effects of c3 - 07 on rho activation from possible inflammatory responses induced by the intravitrial injection of a protein , we used an intentionally inactive mutant of c3 - 07 protein , i . e ., c3 - 07q189a , that lacks adp - ribosylation activity but maintains normal glycohydrolysis activity . to our knowledge , this is the first in vivo study using a mutant c3 exoenzyme or c3 - fusion proteins to study cell survival in the retina . we found that a single injection of c3 - aplt or c3 - 07 promoted survival of rgcs equivalent to rates reported for bdnf , and that the effect of c3 - 07 is dependant on its ability to inactivate rho . other animal models can be used to assess damage to and rescue of photoreceptor cells ( e . g ., reduction in the rate of death of photoreceptor cells ). useful are genetic models of retinal degeneration and other diseases of the eye in mice . the rescue of photoreceptors can be demonstrated in rcs rats that have an inherited retinal degeneration , or in transgenic lines of mice that express mutated forms of rhodospsin that cause retinitis pigmentosa in human . such mice are commercially available from jackson labs . retinal detachement also leads to death . of photoreceptor cells , and this provides another animal model to demonstrate neuroprotection ( e . g ., reduction in the rate of death of photoreceptor cells ). to assess the effect of compounds on neovascularization that occurs in wet macular degeneration and related diseases , animal models are also used . useful to model neovascularization of the retina are rodent models of oxygen - induced retinopathy of the neurobom rodents , sometimes referred to as retinopathy of prematurity ( rop ). c3apl is the name given to the protein made by ligating a cdna encoding c3 ( dillon and feig ( 1995 ) 256 : 174 - 184 ) with cdna encoding the antennapedia homeodomain ( bloch - gallego ( 1993 ) 120 : 485 - 492 ). the stop codon at the 3 ′ end of the dna was replaced with an ecor i site by polymerase chain reaction ( pcr ) using the primers ( oligonucleotides ) 5 ′ gaa ttc ttt agg att gat agc tgt gcc 3 ′ ( seq id no : 1 ) and 5 ′ ggt ggc gac cat cct cca aaa 3 ′ ( seq id no : 2 ). the pcr product was sub - cloned into a pstblue - 1 vector ( novagen , city ), then cloned into a pgex - 4t vector using bamh i and not i restriction site . this vector was called pgex - 4t / c3 . the antennapedia sequence used to add to the 3 ′ end of c3 in pgex - 4t / c3 was created by pcr from the pet - 3a vector ( bloch - gallego ( 1993 ) 120 : 485 - 492 , derossi ( 1994 ) 269 : 10444 - 10450 ), subcloned into a pstblue - 1 blunt vector , then cloned into the pgex - 4t / c3 , using the restriction sites ecor i and sal i , creating pgex - 4t / c3apl . another clone ( c3aplt ) with a frameshift mutation was selected , and the protein made and tested . when the cultures tested positive despite the mutation , the clone was resequenced by another company to confirm the mutation , and this clone was called c3aplt . to confirm the sequence of c3aplt , the coding sequence from both strands was sequenced . the sequence for this clone is given in examples 16 and 17 ( nucleotide sequence of c3aplt ; seq id no : 42 , amino acid sequence of c3aplt ; seq id no : 43 ). a shorter version of the antennapedia ( pgex - 4t / c3aps ) was also made . this chimeric sequence was made by ligating oligonucleotides encoding the short antennapedia peptide ( maizel ( 1999 ) 126 : 3183 - 3190 ) into the pgex - 4t / c3 vector cut with ecor i and sal i . the recombinant c3aplt and c3aps cdnas were separately transformed into bacteria , and after the recombinant proteins were produced , a bacterial homogenate was obtained by sonication , and the homogenate cleared by centrifugation . glutathione - agarose beads ( sigma ) were added to the cleared lysate and placed on a rotating plate for 2 - 3 hours , then washed extensively . to remove the glutathione s transferase sequence from the recombinant protein , 20 u ( unit ) of thrombin was added , the beads were left on a rotator overnight at 4 ° c . after cleavage with thrombin , the beads were loaded into an empty 20 ml column , and the proteins eluted with pbs ( phosphate buffered saline ). aliquots containing recombinant protein were pooled and 100 μl p - aminobenzamidine agarose beads ( sigma ) were added and left mixing for 45 minutes at 4 ° c . to remove thrombin , then recombinant protein was isolated from the beads by centrifugation . purity of the sample was determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis ( sds - page ), and bioactivity bioassay with pc - 12 cells was performed ( see lehmann et al supra ). other possible methods for making bioactive chimeric proteins include anion exchange chromatography . for this , the gst tag is not required and can be removed . the cdna can then be cloned into a high expression bacterial vector , such as pet , as given in example 16 . the rho antagonist is a recombinant protein and can be made according to methods present in the art . the proteins of the present invention may be prepared from bacterial cell extracts , or through the use of recombinant techniques by transformation , transfection , or infection of a host cell with all or part of a c3 - encoding dna fragment with an antennapedia - derived transport sequence in a suitable expression vehicle . those skilled in the field of molecular biology will understand that any of a wide variety of expression systems can be used to provide the recombinant protein . the precise host cell used is not critical to the invention . any fusion protein can be readily purified by utilizing either affinity purification techniques or more traditional column chromatography . affinity techniques include , but are not restricted to gst ( gluathionie - s - transferase ), or the use of an antibody specific for the fusion protein being expressed , or the use of a histidine tag . alternatively , recombinant protein can be fused to an immunoglobulin fc domain . such a fusion protein can be readily purified using a protein a column . it is envisioned that small molecule mimetics of the above - described antagonists are also encompassed by the invention . [ heading - 0379 ] testing the bioactivity of c3aplt , c3aps , c3 - tl and c3 - ts to test the efficacy of c3aplt , c3aps , c3 - tl and c3 - ts a number of experiments were performed with pc - 12 cells , a neural cell line , grown on growth inhibitory substrates ( see lehmann et al supra ). pc - 12 cells were plated on myelin substrates as described ( lehmann et al , supra ). c3 , c3aplt , c3aps , c3 - tl or c3 - ts were added at different concentrations without trituration ( please refer to fig4 and 8 for concentrations used ). c3 added passively to the culture medium in this way was not able to promote neurite growth in the growth inhibitory substrates because cells must be triturated for c3 to enter the cells and be active ( fig1 ). both c3aplt and c3aps were able to adp ribosylate rho to cause a shift in the molecular weight of rhoa ( fig2 ). both c3aplt and c3aps were able to promote neurite growth and enter neurons after being added passively to the culture medium ( fig3 , fig4 and 5 ). dose - response experiment where concentrations of 0 . 25 ng / ml , 2 . 5 ng / ml , 25 ng / ml , 250 ng / ml and 2 . 5 μg / ml ( 2 . 5 microgram / milliliter ) and 25 [ g / ml ( 25 microgram / milliliter ) were tested and showed that c3aplt and c3aps helped more neurons differentiate neurites at doses 10 , 000 fold less than c3 ( fig4 ). dose response experiments where concentrations of 0 . 25 ng / ml , 2 . 5 ng / ml , 25 ng / ml , 250 ng / ml and 2 . 5 μg / ml ( 2 . 5 microgram / milliliter ) and 25 μg / ml ( 25 microgram / milliliter ) were tested and showed that c3aplt was able to promote long neurite growth when added at a minimum concentration of 0 . 0025 ug / ml ( 0 . 0025 microgram / milliliter ) ( fig5 ). these concentrations of 2 . 5 ng / ml and 25 ng / ml for c3aplt and c3aps , represent 10 , 000 and 1 , 000 times less than the dose needed with c3 , respectively . moreover , at the highest concentration tested , 50 ug / ml ( 50 microgram / milliliter ), these two new rho antagonists did not exhibit toxic effects on pc - 12 cells , and were able to stimulate neurite outgrowth on growth inhibitory substrates . c3 - tl and c3 - ts also were tested at concentrations of 0 . 25 ng / ml , 2 . 5 ng / ml , 25 ng / ml , 250 ng / ml and 2 . 5 μg / ml ( 2 . 5 microgram / milliliter ) and 25 μg / ml ( 25 microgram / milliliter ) and were found to be able to promote neurite growth on myelin substrates at doses significantly less than c3 ( fig8 ). c3basic3 was tested at 50 ug / ml in a fast growth assay ( fig1 ). to verify the ability of c3aplt and c3aps to promote growth from primary neurons , primary retinal cultures were prepared , and the neurons were plated on myelin substrates as described with respect to example 5 . in the absence of treatment with c3aplt or c3aps , the cells remained round and were not able to grow neurites . when treated with c3aplt or c3aps , retinal neurons were able to extend long neurites on inhibitory myelin substrates ( fig6 ). next , was tested the ability of c3aplt and c3aps to promote growth on a different type of growth inhibitory substrate relevant to the type of growth inhibitory proteins found at glial scars . chamber slides were coated with a mixture of chondroitin sulfate proteoglycans ( chemicon ), and then plated with retinal neurons ( results presented in fig1 ). the neurons were not able to extend neurites on the proteoglycan substrates , but when treated with c3aplt or c3aps , they extended long neurites . these studies demonstrate that c3aplt and c3aps can be used to promote neurite growth on myelin and on proteoglycans , the major classes of inhibitory substrates that prevent repair after injury in the cns . [ heading - 0384 ] testing ability of c3aplt to promote regeneration and functional recovery after spinal cord injury to test if c3aplt could promote repair after spinal cord injury , fully adult mice were used ( as described with respect to example 6 ). a dorsal hemisection was made at t8 ( thoracic spinal level 8 ), and mice were treated with different amounts ( fig7 ) of c3aplt in a fibrin glue as described ( mckerracher , us patent pending ( delivery patent )). in previous known experiments with c3 , it was found that 40 - 50 μg was needed to promote anatomical regeneration in optic nerve ( lehmann et all supra ). we tested different doses ( see fig7 ) of c3aplt ranging from 1 μg ( 1 microgram / milliliter ) to 50 μg ( 50 microgram / milliliter ) and assessed animals for behavioral recovery according the bbb scale ( basso ( 1995 ) 12 : 1 - 21 ). the day following surgery and application of c3aplt , behavioral testing began . the animals were placed in an open field environment that consisted of a rubber mat approximately 4 ′ by 3 ′ in size . the animals were left to move randomly , the movement of the animals were videotaped . for each test two observers scored the animals for ability to move ankle , knee and hip joints in the early phase of recovery . previously c3 treatment of mice was seen to lead to functional recovery observable 24 hours after treatment . in mice treated with c3aplt , functional recovery could be observed as early as 24 hours after spinal cord injury ( fig7 ). untreated mice exhibit a function recovery score according to the bbb scale averaging 0 , whereas mice treated with c3 are able to walk and have a bbb score averaging 8 ( fig7 ). at higher concentrations of 50 ug , about 50 % of the mice treated with c3aplt died within 24 hours . however , of the mice that survived , they exhibited good long - term functional recovery . these results demonstrate that c3aplt effectively promotes functional recovery early after spinal cord injury , and that it is effective at much lower doses than c3 . however , at high concentrations , c3aplt appears to exhibit toxicity , and therefore careful doing will be required for clinical use . qualitative observations of the videotapes showed that only animals that received c3aplt reached the late phase of recovery after 30 days of treatment . untreated control animals did not typically pass beyond the early phase of recovery . these results indicate that the application of c3aplt improved long - term functional recovery after spinal cord injury compared to no treatment , injury alone , or fibrin adhesive alone . to test if the early recovery was due to neuroprotection , spinal cord sections were examined for apoptosis by tunel labeling following manufacturer &# 39 ; s instruction ( roche diagnostic ). c3aplt was able to reduce the number of dying cells observed at the lesion site . therefore , c3aplt should be an effective neuroprotective agent for treatment of ischemia , such as follows stroke . it has been reported that the long version of antennapedia transport sequence can enhance neurite growth ( bloch - gallego , e ., leroux , i .- , joliot , a . h ., volovitch , m ., henderson , c . e ., prochiantz , a . 1993 . j . cell biol . 120 : 485 ). therefore , this sequence is expected to enhance neurite growth . for the sequence given below , the start site , is in the gst sequence of the plasmid ( not shown ). the vector with the gst sequence is commercially available and thus the entire gst sequence including the start was not sequenced . it was desired to determine only the sequence located 3 ′ to the thrombin cleavage site which releases c3 conjugate from the gst sequence . the gst sequence is cleaved with thrombin . the apl transport sequence ( seq id no . : 44 ) is as follows : val met glu ser arg lys arg ala arg gln thr tyr thr arg tyr gln 1 5 10 15 thr leu glu leu glu lys glu phe his phe asn arg tyr leu thr arg 20 25 30 arg arg arg ile glu ile ala his ala leu cys leu thr glu arg gln 35 40 45 ile lys ile trp phe gln asn arg arg met lys trp lys lys glu asn 50 55 60 ggatcctcta gagtcgacct gcaggcatgc aatgcttatt ccattaatca aaaggcttat 60 tcaaatactt accaggagtt tactaatatt gatcaagcaa aagcttgggg taatgctcag 120 tataaaaagt atggactaag caaatcagaa aaagaagcta tagtatcata tactaaaagc 180 gctagtgaaa taaatggaaa gctaagacaa aataagggag ttatcaatgg atttccttca 240 aatttaataa aacaagttga acttttagat aaatctttta ataaaatgaa gacccctgaa 300 aatattatgt tatttagagg cgacgaccct gcttatttag gaacagaatt tcaaaacact 360 cttcttaatt caaatggtac aattaataaa acggcttttg aaaaggctaa agctaagttt 420 ttaaataaag atagacttga atatggatat attagtactt cattaatgaa tgtctctcaa 480 tttgcaggaa gaccaattat tacacaattt aaagtagcaa aaggctcaaa ggcaggatat 540 attgacccta ttagtgcttt tcagggacaa cttgaaatgt tgcttcctag acatagtact 600 tatcatatag acgatatgag attgtcttct gatggtaaac aaataataat tacagcaaca 660 atgatgggca cagctatcaa tcctaaagaa ttcgtgatgg aatcccgcaa acgcgcaagg 720 cagacataca cccggtacca gactctagag ctagagaagg agtttcactt caatcgctac 780 ttgacccgtc ggcgaaggat cgagatcgcc cacgccctgt gcctcacgga gcgccagata 840 aagatttggt tccagaatcg gcgcatgaag tggaagaagg agaactga 888 gly ser ser arg val asp leu gln ala cys asn ala tyr ser ile asn 1 5 10 15 gln lys ala tyr ser asn thr tyr gln glu phe thr asn ile asp gln 20 25 30 ala lys ala trp gly asn ala gln tyr lys lys tyr gly leu ser lys 35 40 45 ser glu lys glu ala ile val ser tyr thr lys ser ala ser glu ile 50 55 60 asn gly lys leu arg gln asn lys gly val ile asn gly phe pro ser 65 70 75 80 asn leu ile lys gln val glu leu leu asp lys ser phe asn lys met 85 90 95 lys thr pro glu asn ile met leu phe arg gly asp asp pro ala tyr 100 105 110 leu gly thr glu phe gln asn thr leu leu asn ser asn gly thr ile 115 120 125 asn lys thr ala phe glu lys ala lys ala lys phe leu asn lys asp 130 135 140 arg leu glu tyr gly tyr ile ser thr ser leu met asn val ser gln 145 150 155 160 phe ala gly arg pro ile ile thr gln phe lys val ala lys gly ser 165 170 175 lys ala gly tyr ile asp pro ile ser ala phe gln gly gln leu glu 180 185 190 met leu leu pro arg his ser thr tyr his ile asp asp met arg leu 195 200 205 ser ser asp gly lys gln ile ile ile thr ala thr met met gly thr 210 215 220 ala ile asn pro lys glu phe val met glu ser arg lys arg ala arg 225 230 235 240 gln thr tyr thr arg tyr gln thr leu glu leu glu lys glu phe his 245 250 255 phe asn arg tyr leu thr arg arg arg arg ile glu ile ala his ala 260 265 270 leu cys leu thr glu arg gln ile lys ile trp phe gln asn arg arg 275 280 285 met lys trp lys lys glu asn 290 295 molecular weight 34098 . 03 daltons 295 amino acids 48 strongly basic (+) amino acids ( k , r ) 28 strongly acidic (−) amino acids ( d , e ) 89 hydrophobic amino acids ( a , i , l , f , w , v ) 94 polar amino acids ( n , c , q , s , t , y ) 9 . 847 isolectric point 20 . 524 charge at ph 7 . 0 davis , botstein , roth melting temp c . 79 . 48 nucleotide sequence of c3aps ( seq id no : 5 ). the start site , is , in the gst sequence of the plasmid , not shown here . ggatcctcta gagtcgacct gcaggcatgc aatgcttatt ccattaatca aaaggcttat 60 tcaaatactt accaggagtt tactaatatt gatcaagcaa aagcttgggg taatgctcag 120 tataaaaagt atggactaag caaatcagaa aaagaagcta tagtatcata tactaaaagc 180 gctagtgaaa taaatggaaa gctaagacaa aataagggag ttatcaatgg atttccttca 240 aatttaataa aacaagttga acttttagat aaatctttta ataaaatgaa gacccctgaa 300 aatattatgt tatttagagg cgacgaccct gcttatttag gaacagaatt tcaaaacact 360 cttcttaatt caaatggtac aattaataaa acggcttttg aaaaggctaa agctaagttt 420 ttaaataaag atagacttga atatggatat attagtactt cattaatgaa tgtctctcaa 480 tttgcaggaa gaccaattat tacacaattt aaagtagcaa aaggctcaaa ggcaggatat 540 attgacccta ttagtgcttt tcagggacaa cttgaaatgt tgcttcctag acatagtact 600 tatcatatag acgatatgag attgtcttct gatggtaaac aaataataat tacagcaaca 660 atgatgggca cagctatcaa tcctaaagaa ttccgccaga tcaagatttg gttccagaat 720 cgtcgcatga agtggaagaa ggtcgactcg agcggccgca tcgtgactga ctga 774 the aps transport sequence ( seq id no . : 45 ) is as follows : arg gln ile lys ile trp phe gln asn arg arg met lys trp lys lys 1 5 10 15 val asp ser gly ser ser arg val asp leu gln ala cys asn ala tyr ser ile asn 1 5 10 15 gln lys ala tyr ser asn thr tyr gln glu phe thr asn ile asp gln 20 25 30 ala lys ala trp gly asn ala gln tyr lys lys tyr gly leu ser lys 35 40 45 ser glu lys glu ala ile val ser tyr thr lys ser ala ser glu ile 50 55 60 asn gly lys leu arg gln asn lys gly val ile asn gly phe pro ser 65 70 75 80 asn leu ile lys gln val glu leu leu asp lys ser phe asn lys met 85 90 95 lys thr pro glu asn ile met leu phe arg gly asp asp pro ala tyr 100 105 110 leu gly thr glu phe gln asn thr leu leu asn ser asn gly thr ile 115 120 125 asn lys thr ala phe glu lys ala lys ala lys phe leu asn lys asp 130 135 140 arg leu glu tyr gly tyr ile ser thr ser leu met asn val ser gln 145 150 155 160 phe ala gly arg pro ile ile thr gln phe lys val ala lys gly ser 165 170 175 lys ala gly tyr ile asp pro ile ser ala phe gln gly gln leu glu 180 185 190 met leu leu pro arg his ser thr tyr his ile asp asp met arg leu 195 200 205 ser ser asp gly lys gln ile ile ile thr ala thr met met gly thr 210 215 220 ala ile asn pro lys glu phe arg gln ile lys ile trp phe gln asn 225 230 235 240 arg arg met lys trp lys lys val asp ser ser gly arg ile val thr 245 250 255 asp molecular weight 29088 . 22 daltons 257 amino acids 38 strongly basic (+) amino acids ( k , r ) 23 strongly acidic (−) amino acids ( d , e ) 79 hydrophobic amino acids ( a , i , l , f , w , v ) 83 polar amino acids ( n , c , q , s , t , y ) 9 . 745 isolectric point 15 . 211 charge at ph 7 . 0 davis , botstein , roth melting temp c . 78 . 34 c3apl ( amino acid sequence : seq id no . : 4 ) and c3aplt ( amino acid sequence ; seq id no : 37 ) are the names given to the proteins encoded by cdnas made by ligating the functional domain of c3 transferase and the homeobox region of the transcription factor called antennapedia ( bloch - gallego ( 1993 ) 120 : 485 - 492 ) in the following way . a cdna encoding c3 ( dillon and feig ( 1995 ) 256 : 174 - 184 ) cloned in the plasmid vector pgex - 2t was used for the c3 portion of the chimeric protein . the stop codon at the 3 ′ end of the dna was replaced with an ecor i site by polymerase chain reaction using the primers 5 ′ gaa ttc ttt agg att gat agc tgt gcc 3 ′ ( seq id no : 1 ) and 5 ′ ggt ggc gac cat cct cca aaa 3 ′ ( seq id no : 2 ). the pcr product was sub - cloned into a pstblue - 1 vector ( novagen , city ), then cloned into a pgex - 4t vector using bamh i and not i restriction site . this vector was called pgex - 4t / c3 . the pgex - 4t vector has a 5 ′ glutathione s transferase ( gst ) sequence for use in affinity purification . the antennapedia sequence used to add to the 3 ′ end of c3 in pgex - 4t / c3 was created by pcr from the pet - 3a vector ( bloch - gallego ( 1993 ) 120 : 485 - 492 , derossi ( 1994 ) 269 : 10444 - 10450 ). the primers used were 5 ′ gaa tcc cgc aaa cgc gca agg cag 3 ′ ( seq id no : 7 ) and 5 ′ tca gtt ctc ctt ctt cca ctt cat gcg 3 ′ ( seq id no : 8 ). the pcr product obtained from the reaction was subcloned into a pstblue - 1 blunt vector , then cloned into the pgex - 4t / c3 , using the restriction sites ecor i and sal i , creating pgex - 4t / c3apl and c3aplt . c3aplt was selected for the presence of a frameshift mutation giving a transport region moiety rich in prolines . a shorter version of the antennapedia ( pgex - 4t / c3ap - short ) ( amino acid sequence of c3aps ; seq id no . : 6 ) was also made . this chimeric sequence was made by ligating oligonucleotides encoding the short antennapedia peptide ( maizel ( 1999 ) 126 : 3183 - 3190 ) into the pgex - 4t / c3 vector cut with ecor i and sal i . for pgex - 4t / c3ap - short the sequences of the oligos made were 5 ′ aat tcc gcc aga tca aga ttt ggt tcc aga atc gtc gca tga agt gga aga agg 3 ′ ( seq id no : 9 ) and 5 ′ ggc ggt cta gtt cta aac caa gct ctt agc agc gta gtt cac ctt ctt cca gct 3 ′ ( seq id no : 10 ). the two strands were annealed together by mixing equal amounts of the oligonucleotides , heating at 72 ° c . for 5 minutes and then leaving them at room temperature for 15 minutes . the oligonucleotides were ligated into the pgex4t / c3 vector and clones were picked and analyzed . to prepare recombinant c3aplt ( seq id no . : 37 ) and c3aps ( seq id no . : 6 ) proteins , the plasmids containing the corresponding cdnas ( pgex - 4t / c3aplt and pgex - 4t / c3ap - short ) were transformed into bacteria , strain xl - 1 blue competent e . coli . the bacteria were grown in l - broth ( 10 g / l bacto - tryptone , 5 g / l yeast extract , 10 g / l nacl ) with ampicillin at 50 ug / ml ( bmc - roche ), in a shaking incubator for 1 hr at 37 ° c . and 300 rpm . isopropyl . beta .- d - thiogalactopyranoside ( iptg ), ( gibco ) was added to a final concentration of 0 . 5 mm to induce the production of recombinant protein and the culture was grown for a further 6 hours at 37 ° c . and 250 rpm . bacteria pellets were obtained by centrifugation in 250 ml centrifige bottles at 7000 rpm for 6 minutes at 4 ° c . each pellet was re - suspended in 10 ml of buffer a ( 50 mm tris , ph 7 . 5 , 50 mm nacl , 5 mm . mgcl2 , 1 mm dtt ) plus 1 mm pmsf . all re - suspended pellets were pooled and transferred to a 100 ml plastic beaker on ice . the remaining buffer a with pmsf was added to the pooled sample . the bacteria sample was sonicated 6 . times . 20 seconds using a branson sonifier 450 probe sonicator . both the bacteria and probe were cooled on ice 1 minute between sonications . the sonicate was centrifuged in a sorvall ss - 34 rotor at 16 , 000 rpm for 12 minutes at 4 ° c . to clarify the supernatant . the supernatant was transferred into fresh ss - 34 tubes and re - spun at 12 , 000 rpm for 12 minutes at 4 ° c . up to 20 ml of glutathione - agarose beads ( sigma ) were added to the cleared lysate and placed on a rotating plate for 2 - 3 hours . the beads were washed 4 times with buffer b , ( buffer a , nacl is 150 mm , no psmf ) then 2 times with buffer c ( buffer b + 2 . 5 mm cacl2 ). the final wash was poured out till the beads created a thick slurry . to remove the glutathione s transferase sequence from the recombinant protein , 20 u of thrombin ( bovine , plasminogen - free , calbiochem ) was added , the beads were left on a rotator overnight at 4 ° c . after cleavage with thrombin the beads were loaded into an empty 20 ml column . approximately 20 aliquots of 1 ml were collected by elution with pbs . samples of each aliquot of 0 . 5 ul were spotted on nitrocellulose and stained with amido black to determine the protein peak . aliquots containing fusion proteins were pooled and 100 □ 1 ( 100 microliter ) p - aminobenzamidine agarose beads ( sigma ) were added and left mixing for 45 minutes at 4 ° c . this last step removed the thrombin from the recombinant protein sample . the recombinant protein was centrifuged to remove the beads and then concentrated using a centriprep - 10 concentrator ( amicon ). the concentrated recombinant protein was desalted with a pd - 10 column ( pharmacia , containing sephadex g - 25m ) and ten 0 . 5 ml aliquots were collected . a dot - blot was done on these samples to determine the protein peak , and the appropriate aliquots pooled , filter - sterilized , and stored at − 80 ° c . a protein assay ( dc assay , biorad ) was used to determine the concentration of recombinant protein . purity of the sample was determined by sds - page , and bioactivity bioassay with pc - 12 cells . to test the ability of c3aplt and c3aps to overcome growth inhibition , pc - 12 cells were plated on myelin , a growth inhibitory substrate . the myelin was purified from bovine brain ( norton and poduslo ( 1973 ) 21 : 749 - 757 ). in some other experiments chondroitin sulfate proteoglycan ( cspg ) substrates were made from a purchased protein composition ( chemicon ). before coating coverslips or wells of a 96 well plate , they were coated with poly - l - lysine ( 0 . 025 □ g / ml ; 0 . 025 microgram / milliliter ) ( sigma , st . louis , mo . ), washed with water and allowed to dry . myelin stored as a 1 mg / ml solution at − 80 ° c . was thawed at 37 ° c ., and vortexed . the myelin was plated at 8 ug / well in a 8 well chamber lab - tek slides ( nuc , naperville , ill .). the myelin solution was left to dry overnight in a sterile tissue culture hood . the next morning the substrate was washed gently with phosphate buffered saline , and then cells in media were added to the substrate . pc - 12 cells ( lehiann et al ., 1999 ) were grown in dmem with 10 % horse serum ( hs ) and 5 % fetal bovine serum ( fbs ). two days prior to use the pc - 12 cells were differentiated by 50 ng / ml of nerve growth factor ( ngf ). after the cells were primed , 5 ml of trypsin was added to the culture dish to detach the cells , the cells were pelleted and re - suspended in 2 ml of dmem with 1 % hs and 50 ng / ml of nerve growth factor . approximately , 5000 to 7000 cells were then plated on 8 well chamber lab - tek slides ( nuc , naperville , ill .) coated myelin . the cells were placed on the test substrates at 37 ° c . for 3 - 4 hours to allow the cells to settle . the original media was carefully removed by aspiration , taking care not to disrupt the cells and replaced with dmem with 1 % hs , 50 ng / ml of ngf and varying amounts of the c3 , c3aplt , or c3aps , depending on the dose desired . after two days , the cells were fixed ( 4 % paraformaldehyde and 0 . 5 % glutaraldehyde ). for control experiments with unmodified c3 , ngf primed pc - 12 cells were trypsinized to detach them from the culture dish , the cells were washed once with scrape loading buffer ( 114 mm kcl , 15 mm nacl , 5 . 5 mm mgcl2 , and 10 mm tris - hcl ) and then the cells were scraped with a rubber policeman into 0 . 5 ml of scraping buffer in the presence of 25 or 50 □ g / ml ( microgram / milliliter ) of c3 . the cells were pelleted and resuspended in 2 ml of dmem , 1 % hs and 50 ng / ml nerve growth factor before plating . at least four experiments were analyzed for each treatment . for each well , twelve images were collected with a 20 . times . objective using a zeiss axiovert microscope . for each image , the numbers of cells with and without neurites were counted and the lengths of the neurites were determined . since myelin is phase dense , cells plated on myelin substrates were immuno - stained with anti -. beta . iii tubulin antibody before analysis . quantitative analysis of neurite outgrowth was with the aid of northern eclipse software ( empix imaging , mississauga , ontario , canada ). data analysis and statistics were with microsoft excel . for a fast bioassay , the compounds were tested in tissue culture as described above , except that the cells were plated on the tissue culture plastic rather than on inhibitory substrates . for these experiments the plates were fixed and the neurites counted five hours after plating the cells . the test compounds ( c3aplt and c3basic3 ) were able to promote faster growth on tissue culture plastic than cells plated without treatment ( fig1 ). to examine adp ribosylation by c3 , c3aplt , and c3aps , the compounds were added to pc - 12 cell cultures , as described above . the cells were harvested by centrifugation , cell homogenates prepared and the proteins separated by sds polyacrylamide gel electrophoresis . the proteins were then transferred to nitrocellulose and the western blots probed with anti - rhoa antibody ( santa cruz ). testing ability of c3aplt and c3aps to override inhibition of multiple growth inhibitory proteins myelin substrates were made as described in example 4 and plated on tissue culture chamber slides . p1 to p3 rat pups were decapitated , the heads washed in ethanol and the eye removed and placed in a petri dish with hanks buffered saline solution ( hbss , from gibco ). a hole was cut in the cornea , the lens removed , and the retina squeezed out . typically , four retinas per preparation were used . the retinas were removed to a 15 ml tube and the volume brought to 7 ml . a further 7 ml of dissociation enzymes and papain were added . the dissociation enzyme solution was made as follows : 30 mg dl cysteine was added to a 15 ml tube ( sigma dl cystein hydrochloride ), and 70 ml hbss , 280 ul of 10 mg / ml bovine serum albumin were added and the solution mixed and ph adjusted to 7 with 0 . 3 n naoh . the dissociate solution was filter - sterilized and kept frozen in 7 ml aliquots , and before use 12 . 5 units papain per ml ( worthington ) was added . after adding the dissociation solution to the retina , the tube was incubated for 30 minutes on a rocking tray at 37 ° c . the retinas were then gently triturated , centrifuged and washed with hbss . the hbss was replaced with growth medium ( dmem ( gibco ), 10 % fetal bovine serum , and 50 ng / ml brain derived neurotrophic factor ( bdnf ) vitamins , penicillin - streptomycin , in the presence or absence of c3aplt or c3aps . cells were plated on test substrates of myelin or cspg in chamber slides prepared as described in example 4 , above . a quantitative analysis was completed as described for example 4 above . neurons were visualized by fluorescent microscopy with anti -. beta . iii tubulin antibody , which detects growing retinal ganglion cells ( rgcs ). results are presented in fig6 . treatment of injured mouse spinal cord with c3aplt and measurement of recovery of motor function in treated mice adult balb - c mice were anaesthetized with 0 . 6 ml / kg hypnorm , 2 . 5 mg / kg diazepam and 35 mg / kg ketamine . this does gives about 30 minutes of anaesthetic , which is sufficient for the entire operation . a segment of the thoracic spinal column was exposed by removing the vertebrae and spinus process with microrongeurs ( fine science tools ). a spinal cord lesion was then made dorsally , extending past the central canal with fine scissors , and the lesion was recut with a fine knife . this lesion renders all of the control animals paraplegic . the paravertebral muscle were closed with reabsorbable sutures , and the skin was closed with 2 . 0 silk sutures . after surgery , the bladder was manually voided every 8 - 10 hours until the animals regained control , typically 2 - 3 days . food was placed in the cage for easy access , and sponge - water used for easy accessibility of water after surgery . also , animals received subcutaneous injection buprenorphine ( 0 . 05 to 0 . 1 mg / kg ) every 8 - 12 hours for the first 3 days . any animals that lost 15 - 20 % of body weight were killed . rho antagonists ( c3 or c3 - like proteins ) were delivered locally to the site of the lesion by a fibrin - based tissue adhesive delivery system ( mckerracher , canadian patent application no . 2 , 325 , 842 ). recombinant c3aplt was mixed with fibrinogen and thrombin in the presence of cacl2 . fibrinogen is cleaved by thrombin , and the resulting fibrin monomers polymerize into a three - dimensional matrix . we added c3aplt as part of a fibrin adhesive , which polymerized within about 10 seconds after being placed in the injured spinal cord . we tested c3aplt applied to the spinal cord lesion site after the lesion was made . for control we injected fibrin adhesive alone , or transected the cord without further treatment . for behavioral testing , the bbb scoring method was used to examine locomotion in an open field environment ( basso ( 1995 ) 12 : 1 - 21 ). results are presented in fig7 . the environment was a rubber mat approximately 4 ′. times . 3 ′ in size , and animals were placed on the mat and videotaped for about 4 minutes . care was taken not to stimulate the peroneal region or touch the animals excessively during the taping session . the video tapes were digitized and observed by two observers to assign bbb scores . the bbb score , modified for mice , was as follows : score description 1 no observable hindlimb ( hl ) movement . 2 slight movement of one or two joints . 3 extensive movement of one joint and / or slight movement of one other joint . 4 extensive movement of two joints . 5 slight movement of all three joints of the hl . 6 slight movement of two joints and extensive movement of the third . 7 extensive movement of two joints and slight movement of the third . 8 extensive movement of all three joints of the hl walking with no weight support . 9 extensive movement of all three joints , walking with weight support . 10 frequent to consistent dorsal stepping with weight support . 11 frequent plantar stepping with weight support . 12 consistent plantar stepping with weight support , no coordination . 13 consistent plantar stepping with consistent weight support , occasional fl - hl coordination . 14 consistent plantar stepping with consistent weight support , frequent fl - hl coordination . 15 consistent plantar stepping with consistent weight support , consistent fl - hl coordination ; predominant paw position during locomotion is rotated internally or externally , or consistent fl - hl coordination with occasional dorsal stepping . 16 consistent plantar stepping with consistent weight support , consistent fl - hl coordination ; predominant paw position is parallel to the body ; frequent to consistent toe drag , or curled toes , trunk instability . 17 consistent plantar stepping with consistent weight support , consistent fl - hl coordination ; predominant paw position is parallel to the body , no toe drag , some trunk instability . 18 consistent plantar stepping with consistent weight support , consistent fl - hl coordination ; predominant paw position is parallel to the body , no toe drag and consistent stability in the locomotion . treatment of injured mouse spinal cord with c3aplt and assessment of anatomical recovery mice that received a spinal cord injury and treated as controls or with c3aplt , as described for example 6 were assessed for morphological changes to the scar and for axon regeneration . to study axon regeneration , the corticospinal axons were identified by anterograde labeling . for anterograde labeling studies , the animals were anaesthetized as above , and the cranium over the motor cortex was removed . with the fine glass micropipetter ( about 100 um in diameter ) the cerebral cortex was injected with 2 - 4 ul of horse radish peroxidase conjugated to wheat germ agglutinin ( 2 %), a marker that is taken up by nerve cells and transported anterogradely into the axon that extends into the spinal cord . after injection of the anterograde tracer , the cranium was replaced , and the skin closed with 5 - 0 silk sutures . the animals were sacrificed with chloral hydrate ( 4 . 9 mg / 10 g ) after 48 hours , and perfused with 4 % paraformaldehyde in phosphate buffer as a fixative . the spinal cord was removed , cryoprotected with sucrose and cryostat sections placed on slides for histological examination . the tat coding sequence was obtained by polymerase chain reaction of the plasmid svcmv - tat ( obtained form dr . eric cohen , universite de montreal ) that contains the entire hiv - 1 tat coding sequence . to isolate the transport sequence of the tat protein , pcr was used . the first primer ( 5 ′ gaatccaagcaccaggaagtcagcc 3 ′ ( seq id no . : 11 )) and the second primer ( 5 ′ acc agccaccaccttctgata 3 ′ ( seq id no . : 12 )) used corresponded to amino acids 27 to 72 of the hiv tat protein . upon verification and purification , the pcr product was sub cloned into a pstblue - 1 blunt vector . this transport segment of the tat protein was then cloned into pgex - 4t / c3 at the 3 ′ end of c3 , using the restriction sites ecor i and sac i . the new c3 - tat fusion protein was called c3 - tl . recombinant protein was made as described in example 3 . ggatcctcta gagtcgacct gcaggcatgc aatgcttatt ccattaatca aaaggcttat 60 tcaaatactt accaggagtt tactaatatt gatcaagcaa aagcttgggg taatgctcag 120 tataaaaagt atggactaag caaatcagaa aaagaagcta tagtatcata tactaaaagc 180 gctagtgaaa taaatggaaa gctaagacaa aataagggag ttatcaatgg atttccttca 240 aatttaataa aacaagttga acttttagat aaatctttta ataaaatgaa gacccctgaa 300 aatattatgt tatttagagg cgacgaccct gcttatttag gaacagaatt tcaaaacact 360 cttcttaatt caaatggtac aattaataaa acggcttttg aaaaggctaa agctaagttt 420 ttaaataaag atagacttga atatggatat attagtactt cattaatgaa tgtctctcaa 480 tttgcaggaa gaccaattat tacacaattt aaagtagcaa aaggctcaaa ggcaggatat 540 attgacccta ttagtgcttt tcagggacaa cttgaaatgt tgcttcctag acatagtact 600 tatcatatag acgatatgag attgtcttct gatggtaaac aaataataat tacagcaaca 660 atgatgggca cagctatcaa tcctaaagaa ttcaagcatc caggaagtca gcctaaaact 720 gcttgtacca attgctattg taaaaagtgt tgctttcatt gccaagtttg tttcataaca 780 aaagccttag gcatctccta tggcaggaag cggagacagc gacgaagagc tcatcagaac 840 agtcagactc atcaagcttc tctatcaaag cagtaa 876 the tl transport peptide sequence by itself is as follows :( seq id no . : 46 ) lys his pro gly ser gln pro lys thr ala cys thr asn cys tyr cys 1 5 10 15 lys lys cys cys phe his cys gln val cys phe ile thr lys ala leu 20 25 30 gly ile ser tyr gly arg lys arg arg gln arg arg ala his gln asn 35 40 45 ser gln thr his gln ala ser leu ser lys gln 50 55 gly ser ser arg val asp leu gln ala cys asn ala tyr ser ile asn 1 5 10 15 gln lys ala tyr ser asn thr tyr gln glu phe thr asn ile asp gln 20 25 30 ala lys ala trp gly asn ala gln tyr lys lys tyr gly leu ser lys 35 40 45 ser glu lys glu ala ile val ser tyr thr lys ser ala ser glu ile 50 55 60 asn gly lys leu arg gln asn lys gly val ile asn gly phe pro ser 65 70 75 80 asn leu ile lys gln val glu leu leu asp lys ser phe asn lys met 85 90 95 lys thr pro glu asn ile met leu phe arg gly asp asp pro ala tyr 100 105 110 leu gly thr glu phe gln asn thr leu leu asn ser asn gly thr ile 115 120 125 asn lys thr ala phe glu lys ala lys ala lys phe leu asn lys asp 130 135 140 arg leu glu tyr gly tyr ile ser thr ser leu met asn val ser gln 145 150 155 160 phe ala gly arg pro ile ile thr gln phe lys val ala lys gly ser 165 170 175 lys ala gly tyr ile asp pro ile ser ala phe gln gly gln leu glu 180 185 190 met leu leu pro arg his ser thr tyr his ile asp asp met arg leu 195 200 205 ser ser asp gly lys gln ile ile ile thr ala thr met met gly thr 210 215 220 ala ile asn pro lys glu phe lys his pro gly ser gln pro lys thr 225 230 235 240 ala cys thr asn cys tyr cys lys lys cys cys phe his cys gln val 245 250 255 cys phe ile thr lys ala leu gly ile ser tyr gly arg lys arg arg 260 265 270 gln arg arg arg ala his gln asn ser gln thr his gln ala ser leu 275 280 285 ser lys gln 290 molecular weight 32721 . 40 daltons 291 amino acids 43 strongly basic (+) amino acids ( k , r ) 21 strongly acidic (−) amino acids ( d , e ) 82 hydrophobic amino acids ( a , i , l , f , w , v ) 104 polar amino acids ( n , c , q , s , t , y ) 9 . 688 isolectric point 22 . 655 charge at ph 7 . 0 % a = 37 . 44 [ 328 ] % g = 17 . 58 [ 154 ] % t = 28 . 31 [ 248 ] % c = 16 . 67 [ 146 ] a shorter tat construct was also made ( c3 - ts ). to make the shorter c3 tat fusion protein the following oligonucleotides were 5 ′ aat tct atg gtc gta aaa aac gtc gtc aac gtc gtc gtg 3 ′ ( seq id no . : 15 ) and 5 ′ gat acc agc att ttt tgc agc agt tgc agc agc aca gct 3 ′ ( seq id no . : 16 ). the two oligonucleotide strands were annealed together by combining equal amounts of the oligonucleotides , heating at 72 ° c . for 5 minutes and then letting the oligonucleotide solution cool at room temperature for 15 minutes . the oligonucleotides were ligated into the pgex4t / c3 vector at the 3 ′ end of c3 . the construct was sequenced . all plasmids were transformed into xl - 1 blue competent cells . recombinant protein was made as described in example 3 . ggatcctcta gagtcgacct gcaggcatgc aatgcttatt ccattaatca aaaggcttat 60 tcaaatactt accaggagtt tactaatatt gatcaagcaa aagcttgggg taatgctcag 120 tataaaaagt atggactaag caaatcagaa aaagaagcta tagtatcata tactaaaagc 180 gctagtgaaa taaatggaaa gctaagacaa aataagggag ttatcaatgg atttccttca 240 aatttaataa aacaagttga acttttagat aaatctttta ataaaatgaa gacccctgaa 300 aatattatgt tatttagagg cgacgaccct gcttatttag gaacagaatt tcaaaacact 360 cttcttaatt caaatggtac aattaataaa acggcttttg aaaaggctaa agctaagttt 420 ttaaataaag atagacttga atatggatat attagtactt cattaatgaa tgtctctcaa 480 tttgcaggaa gaccaattat tacacaattt aaagtagcaa aaggctcaaa ggcaggatat 540 attgacccta ttagtgcttt tcagggacaa cttgaaatgt tgcttcctag acatagtact 600 tatcatatag acgatatgag attgtcttct gatggtaaac aaataataat tacagcaaca 660 atgatgggca cagctatcaa tcctaaagaa ttctatggtg ctaaaaaacg tcgtcaacgt 720 cgtcgtgtcg actcgagcgg cccgcatcgt gactga 756 the ts transport peptide sequence by itself is as follows : ( seq id no . : 47 ) tyr gly ala lys lys arg arg gln arg arg arg val asp ser ser gly 1 5 10 15 pro his arg asp 20 gly ser ser arg val asp leu gln ala cys asn ala tyr ser ile asn 1 5 10 15 gln lys ala tyr ser asn thr tyr gln glu phe thr asn ile asp gln 20 25 30 ala lys ala trp gly asn ala gln tyr lys lys tyr gly leu ser lys 35 40 45 ser glu lys glu ala ile val ser tyr ile lys ser ala ser glu thr 50 55 60 asn gly lys leu arg gln asn lys gly val ile asn gly phe pro ser 65 70 75 80 asn leu ile lys gln val glu leu leu asp lys ser phe asn lys met 85 90 95 lys thr pro glu asn ile met leu phe arg gly asp asp pro ala tyr 100 105 110 leu gly thr glu phe gln asn thr leu leu asn ser asn gly thr ile 115 120 125 asn lys thr ala phe glu lys ala lys ala lys phe leu asn lys asp 130 135 140 arg leu glu tyr gly tyr ile ser thr ser leu met asn val ser gln 145 150 155 160 phe ala gly arg pro ile ile thr gln phe lys val ala lys gly ser 165 170 175 lys ala gly tyr ile asp pro ile ser ala phe gln gly gln leu glu 180 185 190 met leu leu pro arg his ser thr tyr his ile asp asp met arg leu 195 200 205 ser ser asp gly lys gln ile ile ile thr ala thr met met gly thr 210 215 220 ala ile asn pro lys glu phe tyr gly ala lys lys arg arg gln arg 225 230 235 240 arg arg val asp ser ser gly pro his arg asp 245 250 molecular weight 26866 . 62 daltons 238 amino acids 36 strongly basic (+) amino acids ( k , r ) 21 strongly acidic (−) amino acids ( d , e ) 71 hydrophobic amino acids ( a , i , l , f , w , v ) 78 polar amino acids ( n , c , q , s , t , y ) 9 . 802 isolectric point 15 . 212 charge at ph 7 . 0 % a = 38 . 91 [ 279 ] % g = 17 . 43 [ 125 ] % t = 28 . 45 [ 204 ] % c = 15 . 20 [ 109 ] the following example illustrates how a coding sequence can be modified without affecting the efficacy of the translated protein . the example shows modifications to c3basic3 that would not affect the activity . sequences may include the entire gst sequence , as shown here that includes the start site , which would not be removed enzymatically . also , the transport sequence shown in this example has changes in amino acid composition surrounding the active sequence due to a difference in the cloning strategy , and the his tag has been omitted . however , the active region is : r r k q r r k r r ( seq id no : 53 ). this sequence is contained in the c3basic3 , and is the active transport sequence in the sequence below . also note that the c - terminal region of the protein after this active region differs from c3basic3 . that is because the cloning strategy was changed , the restriction sites differ , and therefore non - essential amino acids 3 ′ terminal to the transport sequence are transplanted and included in the protein . atgtccccta tactaggtta ttggaaaatt aagggccttg tgcaacccac tcgacttctt 60 ttggaatatc ttgaagaaaa atatgaagag catttgtatg agcgcgatga aggtgataaa 120 tggcgaaaca aaaagtttga attgggtttg gagtttccca atcttcctta ttatattgat 180 ggtgatgtta aattaacaca gtctatggcc atcatacgtt atatagctga caagcacaac 240 atgttgggtg gttgtccaaa agagcgtgca gagatttcaa tgcttgaagg agcggttttg 300 gatattagat acggtgtttc gagaattgca tatagtaaag actttgaaac tctcaaagtt 360 gattttctta gcaagctacc tgaaatgctg aaaatgttcg aagatcgttt atgtcataaa 420 acatatttaa atggtgatca tgtaacccat cctgacttca tgttgtatga cgctcttgat 480 gttgttttat acatggaccc aatgtgcctg gatgcgttcc caaaattagt ttgttttaaa 540 aaacgtattg aagctatccc acaaattgat aagtacttga aatccagcaa gtatatagca 600 tggcctttgc agggctggca agccacgttt ggtggtggcg accatcctcc aaaatcggat 660 ctggttccgc gtggatcctc tagagtcgac ctgcaggcat gcaatgctta ttccattaat 720 caaaaggctt attcaaatac ttaccaggag tttactaata ttgatcaagc aaaagcttgg 780 ggtaatgctg agtataaaaa gtatggacta agcaaatcag aaaaagaagc tatagtatca 840 tatactaaaa gcgctagtga aataaatgga aagctaagac aaaataaggg agttatcaat 900 ggatttcctt caaatttaat aaaacaagtt gaacttttag ataaatcttt taataaaatg 960 aagacccctg aaaatattat gttatttaga ggcgaggagc ctgcttattt aggaacagaa 1020 tttcaaaaca ctcttcttaa ttcaaatggt acaattaata aaacggcttt tgaaaaggct 1080 aaagctaagt ttttaaataa agatagactt gaatatggat atattagtac ttcattaatg 1140 aatgtttctc aatttgcagg aagaccaatt attacaaaat ttaaagtagc aaaaggctca 1200 aaggcaggat atattgagcc tattagtgct tttcagggac aacttgaaat gttgcttcct 1260 agacatagta cttatcatat agacgatatg agattgtctt ctgatggtaa acaaataata 1320 attacagcaa caatgatggg cacagctatc aatcctaaag aattcagaag gaaacaaaga 1380 agaaaaagaa gactgcaggc ggccgcatcg tga 1413 met ser pro ile leu gly tyr trp lys ile lys gly leu val gln pro 1 5 10 15 thr arg leu leu leu glu tyr leu glu glu lys tyr glu glu his leu 20 25 30 tyr glu arg asp glu gly asp lys trp arg asn lys lys phe glu leu 35 40 45 gly leu glu phe pro asn leu pro tyr tyr ile asp gly asp val lys 50 55 60 leu thr gln ser met ala ile ile arg tyr ile ala asp lys his asn 65 70 75 80 met leu gly gly cys pro lys glu arg ala glu ile ser met leu glu 85 90 95 gly ala val leu asp ile arg tyr gly val ser arg ile ala tyr ser 100 105 110 lys asp phe glu thr leu lys val asp phe leu ser lys leu pro glu 115 120 125 met leu lys met phe glu asp arg leu cys his lys thr tyr leu asn 130 135 140 gly asp his val thr his pro asp phe met leu tyr asp ala leu asp 145 150 155 160 val val leu tyr met asp pro met cys leu asp ala phe pro lys leu 165 170 175 val cys phe lys lys arg ile glu ala ile pro gln ile asp lys tyr 180 185 190 leu lys ser ser lys tyr ile ala trp pro leu gln gly trp gln ala 195 200 205 thr phe gly gly gly asp his pro pro lys ser asp leu val pro arg 210 215 220 gly ser ser arg val asp leu gln ala cys asn ala tyr ser ile asn 225 230 235 240 gln lys ala tyr ser asn thr tyr gln glu phe thr asn thr asp gln 245 250 255 ala lys ala trp gly asn ala gln tyr lys lys tyr gly leu ser lys 260 265 270 ser glu lys glu ala ile val ser tyr thr lys ser ala ser glu thr 275 280 285 asn gly lys leu arg gln asn lys gly val ile asn gly phe pro ser 290 295 300 asn leu ile lys gln val glu leu leu asp lys ser phe asn lys met 305 310 315 320 lys thr pro glu asn ile met leu phe arg gly asp asp pro ala tyr 325 330 335 leu gly thr glu phe gln asn thr leu leu asn ser asn gly thr ile 340 345 350 asn lys thr ala phe glu lys ala lys ala lys phe leu asn lys asp 355 360 365 arg leu glu tyr gly tyr ile ser thr ser leu met asn val ser gln 370 375 380 phe ala gly arg pro ile ile thr arg phe lys val ala lys gly ser 385 390 395 400 lys ala gly tyr ile asp pro ile ser ala phe gln gly gln leu glu 405 410 415 met leu leu pro arg his ser thr tyr his asp asp met arg leu ser 420 425 430 ser asp gly lys gln ile ile ile thr ala thr met met gly thr ala 435 440 445 ile asn pro lys glu phe arg arg lys gln arg arg lys arg arg leu 450 455 460 gln ala ala ala ser 465 molecular weight 53813 . 02 daltons 470 amino acids 68 strongly basic (+) amino acids ( k , r ) 55 strongly acidic (−) amino acids ( d , e ) 149 hydrophobic amino acids ( a , i , l , f , w , v ) 121 polar amino acids ( n , c , q , s , t , y ) 9 . 137 isolectric point 14 . 106 charge at ph 7 . 0 % a = 34 . 61 [ 489 ] % g = 19 . 75 [ 279 ] % t = 29 . 51 [ 417 ] % c = 15 . 99 [ 226 ] % ambiguous = 0 . 14 [ 2 ] % a + t = 64 . 12 [ 906 ] % c + g = 35 . 74 [ 505 ] additional chimeric c3 proteins that would be effective to stimulate repair in the cns the following sequences could be added to the amino terminal or carboxy terminal of c3 or a truncated c3 that retains its enzymatic activity . ( 1 ) sequences of polyarginine as described ( wender , et al . ( 2000 ) 97 : 13003 - 8 .). these could be from 6 to 9 or more arginines . ( 2 ) sequences of poly - lysine ( 3 ) sequences of poly - histidine ( 4 ) sequences of arginine and lysine mixed . ( 5 ) basic stretches of amino acids containing non - basic amino acids stretch where the sequence added retains transport characteristics . ( 6 ) sequences of 5 - 15 amino acids containing at least 50 % basic amino acids ( 7 ) sequences longer than 15 - 30 amino acids containing at least 30 % basic amino acids . ( 8 ) sequences longer than 50 amino acids containing at least 18 % basic amino acids . ( 9 ) any of the above where the amino acids are chemically modified , such as by addition of cyclohexyl side chains , other side chains , different alkyl spacers . ( 10 ) sequences that have proline residues with helix - breaking propensity to act as effective transporters . additional chimeric c3 proteins that would be effective to stimulate repair in the cns we have designed the following dna encoding a chimeric c3 with membrane transport properties . the protein is designated c3basic1 . this sequence was designed with c3 fused to a random basic sequence . the construct was made to encode the peptide given below . the construct was made by synthesizing the two oligonucleotides given below , annealing them together , and ligating them into the pgex - 4t / c3 vector with an added histidine tag . aagagaaggc gaagaagacc taagaagaga cgaagggcga agaggaga 48 ( seq id no : 22 ) ttctcttccg cttcttctgg attcttctct gcttcccgct tctcctct 48 ( seq id no : 23 ) ggatcctcta gagtcgacct gcaggcatgc aatgcttatt ccattaatca aaaggcttat 60 tcaaatactt accaggagtt tactaatatt gatcaagcaa aagcttgggg taatgctcag 120 tataaaaagt atggactaag caaatcagaa aaagaagcta tagtatcata tactaaaagc 180 gctagtgaaa taaatggaaa gctaagacaa aataagggag ttatcaatgg atttccttca 240 aatttaataa aacaagttga acttttagat aaatctttta ataaaatgaa gacccctgaa 300 aatattatgt tatttagagg cgacgaccct gcttatttag gaacagaatt tcaaaacact 360 cttcttaatt caaatggtac aattaataaa acggcttttg aaaaggctaa agctaagttt 420 ttaaataaag atagacttga atatggatat attagtactt cattaatgaa tgtttctcaa 480 tttgcaggaa gaccaattat tacaaaattt aaagtagcaa aaggctcaaa ggcaggatat 540 attgacccta ttagtgcttt tcagggacaa cttgaaatgt tgcttcctag acatagtact 600 tatcatatag acgatatgag attgtcttct gatggtaaac aaataataat tacagcaaca 660 atgatgggca cagctatcaa tcctaaagaa ttcaagagaa ggcgaagaag acctaagaag 720 agacgaaggg cgaagaggag acaccaccac caccaccacg tcgactcgag cggccgcatc 780 gtgactgact ga 792 molecular weight 29897 . 03 daltons 263 amino acids 44 strongly basic (+) amino acids ( k , r ) 23 strongly acidic (−) amino acids ( d , e ) 75 hydrophobic amino acids ( a , i , l , f , w , v ) 79 polar amino acids ( n , c , q , s , t , y ) 10 . 024 isolectric point 22 . 209 charge at ph 7 . 0 davis , botstein , roth melting temp c . 78 . 56 additional chimeric c3 protein that would be effective to stimulate repair in the cns we have designed the following dna encoding a chimeric c3 with membrane transport properties . the protein is designated c3basic2 . this sequence was designed with c3 fused to a random basic sequence . the construct was made to encode the peptide given below . the construct was made by synthesizing the two oligonucleotides given below , annealing them together , and ligating them into the pgex4t / c3 vector with an added histidine tag . ( seq id no . : 27 ) aagcgtcgac gtagaaagaa acgtagacag cgtagacgt 39 ( seq id no . : 28 ) ttcgcagctg catctttctt tgcatctgtc gcatctgca 39 5 ′ gga tcc tct aga gtc gac ctg cag gca tgc aat gct tat tcc att aat caa aag gct tat tca aat act tac cag gag ttt act aat att gat caa gca aaa gct tgg ggt aat gct cag tat aaa aag tat gga cta agc aaa tca gaa aaa gpa gct ata gta tca tat act aaa agc gct agt gaa ata aat gga aag cta aga caa aat aag gga gtt atc aat gga ttt cct tca aat tta ata aaa caa gtt gaa ctt tta gat paa tct ttt aat aaa atg aag acc cct gaa aat att atg tta ttt aga ggc gac gac cct gct tat tta gga aca gpa ttt cpa aac act ctt ctt aat tca aat ggt aca att aat aaa acg gct ttt gaa aag gct aaa gct aag ttt tta aat aaa gat aga ctt gaa tat gga tat att agt act tca tta atg aat gtt tct caa ttt gca gga aga cca att att aca aaa ttt aaa gta gca aaa ggc tca aag gca gga tat att gac cct att agt gct ttt cag gga caa ctt gaa atg ttg ctt cct aga cat agt act tat cat ata gac gat atg aga ttg tct tct gat ggt aaa caa ata ata att aca gca aca atg atg ggc aca gct atc aat cct aaa gaa ttc aag cgt cga cgt aga aag aaa cgt aga cag cgt aga cgt cac cac cac cac cac cac gtc gac tcg agc ggc cgc atc gtg act gac tga 3 ′ gly ser ser arg val asp leu gln ala cys asn ala 1 5 10 tyr ser ile asn gln lys ala tyr ser asn thr tyr 15 20 gln glu phe thr asn asp gln ala lys ala trp gly 25 30 35 asn ala gln tyr lys lys tyr gly leu ser lys ser 40 45 glu lys glu ala ile val ser tyr thr lys ser ala 50 55 60 ser glu thr asn gly lys leu arg gln asn lys gly 65 70 val thr asn gly phe pro ser asn leu ile lys gln 75 80 val glu leu leu asp lys ser phe asn xaa met lys 85 90 95 thr pro glu asn thr met leu phe arg gly asp asp 100 105 pro ala tyr leu gly thr glu phe gln asn thr leu 110 115 120 leu asn ser asn gly thr ile asn lys thr ala phe 125 130 glu lys ala lys ala lys phe leu asn lys asp arg 135 140 leu glu tyr gly tyr ile ser thr ser leu met asn 145 150 155 val ser gln phe ala gly arg pro ile ile thr lys 160 165 phe lys val ala lys gly ser lys ala gly tyr ile 170 175 180 asp pro ile ser ala phe gln gly gln leu glu met 185 190 leu leu pro arg his ser thr tyr his thr asp asp 195 200 met arg leu ser ser asp gly lys gln ile ile ile 205 210 215 thr ala thr met met gly thr ala thr asn pro lys 220 225 glu phe lys arg arg arg arg lys lys arg arg gln 230 235 240 arg arg arg his his his his his his val asp ser 245 250 ser gly arg ile val thr asp 255 molecular weight 29572 . 61 daltons 260 amino acids 42 strongly basic (+) amino acids ( k , r ) 23 strongly acidic (−) amino acids ( d , e ) 74 hydrophobic amino acids ( a , i , l , f , w , v ) 80 polar amino acids ( n , c , q , s , t , y ) 9 . 956 isolectric point 20 . 210 charge at ph 7 . 0 davis , botstein , roth melting temp c . 78 . 45 additional chimeric c3 protein that would be effective to stimulate repair in the cns we have designed the following dna encoding a chimeric c3 with membrane transport properties . the protein is designated c3basic3 . this sequence was designed with c3 fused to a reverse tat sequence . the construct was made to encode the peptide given below the construct was made by synthesizing the two oligonucleotides given below , annealing them together , and ligating them into the pgex4t / c3 vector with an added histidine tag , then subcloning in pgex - 4t / c3 . agaaggaaac aaagaagaaa aagaaga 27 ( seq id no . : 32 ) tcttcctttg tttcttcttt ttcttct 27 ( seq id no . : 33 ) ggatcctcta gagtcgacct gcaggcatgc aatgcttatt 60 ccattaatca aaaggcttat tcaaatactt accaggagtt tactaatatt gatcaagcaa 120 aagcttgggg taatgctcag tataaaaagt atggactaag caaatcagaa aaagaagcta 180 tagtatcata tactaaaagc gctagtgaaa taaatggaaa gctaagacaa aataagggag 240 ttatcaatgg atttccttca aatttaataa aacaagttga acttttagat aaatctttta 300 ataaaatgaa gacccctgaa aatattatgt tatttagagg cgacgaccct gcttatttag 360 gaacagaatt tcaaaacact cttcttaatt caaatggtac aattaataaa acggcttttg 420 aaaaggctaa agctaagttt ttaaataaag atagacttga atatggatat attagtactt 480 cattaatgaa tgtttctcaa tttgcaggaa gaccaattat tacaaaattt aaagtagcaa 540 aaggctcaaa ggcaggatat attgacccta ttagtgcttt tcagggacaa cttgaaatgt 600 tgcttcctag acatagtact tatcatatag acgatatgag attgtcttct gatggtaaac 660 aaataataat tacagcaaca atgatgggca cagctatcaa tcctaaagaa ttcagaagga 720 aacaaagaag aaaaagaaga caccaccacc accaccacgt cgactcgagc ggccgcatcg 771 tgactgactg a gly ser ser arg val asp leu gln ala cys asn ala 1 5 10 tyr ser thr asn gln lys ala tyr ser asn thr tyr 15 20 gln glu phe thr asn ile asp gln ala lys ala trp 25 30 35 gly asn ala gln tyr lys lys tyr gly leu ser lys 40 45 ser glu lys ile glu ala ile val ser tyr thr lys 50 55 60 ser ala ser glu ile asn gly lys leu arg gln asn 65 70 lys gly val ile asn gly phe pro ser asn ile lys 75 80 gln val glu leu leu asp lys ser phe asn lys met 85 90 95 lys thr pro glu asn ile met leu phe arg gly asp 100 105 asp pro ala tyr leu gly thr glu phe gln asn thr 110 115 120 leu leu asn ser asn gly thr thr asn lys thr ala 125 130 phe glu lys ala lys ala lys phe leu asn lys asp 135 140 arg leu glu tyr gly tyr ile ser thr ser leu met 145 150 155 asn val ser gln phe ala gly arg leu pro ile ile 160 165 thr arg phe lys val ala lys gly ser lys ala gly 170 175 180 tyr ile asp pro ile ser ala phe gln gly gln leu 185 190 glu met leu leu ala arg his ser thr tyr his ile 195 200 asp asp met arg leu ser ser asp gly lys gln ile 205 210 215 ile ile thr ala thr met met gly thr ala ile asn 220 225 pro lys glu phe arg arg lys gln arg arg lys arg 230 235 240 arg his his his his his his val asp ser ser gly 245 250 arg ile val thr asp 255 molecular weight 29441 . 47 daltons 260 amino acids 39 strongly basic (+) amino acids ( k , r ) 23 strongly acidic (−) amino acids ( d , e ) 76 hydrophobic amino acids ( a , i , l , f , w , v ) 80 polar amino acids ( n , c , q , s , t , y ) 9 . 833 isolectric point 17 . 211 charge at ph 7 . 0 davis , botstein , roth melting temp c . 78 . 29 one of the clones that was selected from the subcloning of c3apl into pgex encoded a protein that was not the expected size but had good biological activity . this clone that had a frameshift mutation leading to a truncation , and this clone was called c3aplt . the clone was resequenced and the chromatograms analyzed to confirm the sequence . to confirm the sequences of c3aplt , the coding sequence from both strands of pgex - 4t / c3aplt were sequenced by double strand sequencing of the full length of the clone ( bios & amp ; t , montreal , quebec ). the dna sequence for c3aplt is as follows : ( seq id no . : 36 ) ggatcctcta gagtcgacct gcaggcatgc aatgcttatt 60 ccattaatca aaaggcttat tcaaatactt accaggagtt tactaatatt gatcaagcaa 120 aagcttgggg taatgctcag tataaaaagt atggactaag caaatcagaa aaagaagcta 180 tagtatcata tactaaaagc gctagtgaaa taaatggaaa gctaagacaa aataagggag 240 ttatcaatgg atttccttca aatttaataa aacaagttga acttttagat aaatctttta 300 ataaaatgaa gacccctgaa aatattatgt tatttagagg cgacgaccct gcttatttag 360 gaacagaatt tcaaaacact cttcttaatt caaatggtac aattaataaa acggcttttg 420 aaaaggctaa agctaagttt ttaaataaag atagacttga atatggatat attagtactt 480 cattaatgaa tgtttctcaa tttgcaggaa gaccaattat tacaaaattt aaagtagcaa 540 aaggctcaaa ggcaggatat attgacccta ttagtgcttt tgcaggacaa cttgaaatgt 600 tgcttcctag acatagtact tatcatatag acgatatgag attgtcttct gatggtaaac 660 aaataataat tacagcaaca atgatgggca cagctatcaa tcctaaagaa ttcgtgatga 720 atcccgcaaa cgcgcaaggc agacatacac ccggtaccag actctagagc tagagaagga 780 gtttcacttc aatcgctact tgacccgtcg gcgaaggatc gagatcgccc acgccctgtg 840 cctcacggag cgccagataa agatttggtt ccagaatcgg cgcatgaagt ggaagaagga 887 gaactga the aplt transport peptide sequence by itself is as follows ( seq id no . : 48 ): val met asn pro ala asn ala gln gly arg his thr 1 5 10 pro gly thr arg leu 15 the protein sequence for c3aplt is as follows : ( seq id no . : 37 ) gly ser ser arg val asp leu gln ala cys asn ala 1 5 10 tyr ser ile asn gln lys ala tyr ser asn thr tyr 15 20 gln glu phe thr asn ile asp gln ala lys ala trp 25 30 35 gly asn ala gln tyr lys lys tyr gly leu ser lys 40 45 ser glu lys ile glu ala ile val ser tyr thr lys 50 55 60 ser ala ser glu ile asn gly lys leu arg gln asn 65 70 lys gly val ile asn gly phe pro ser asn leu ile 75 80 lys gln val glu leu leu asp lys ser phe asn lys 85 90 95 met lys thr pro glu asn ile met leu phe arg gly 100 105 asp asp pro ala tyr leu gly thr glu phe gln asn 110 115 120 thr leu leu asn ser asn gly thr ile asn lys thr 125 130 ala phe glu lys ala lys ala lys phe leu asn ile 135 140 lys asp arg leu glu tyr gly tyr ile ser thr ser 145 150 155 leu met asn val ser gln phe ala gly arg pro ile 160 165 ile thr lys phe lys val ala lys gly ser lys ala 170 175 180 gly tyr ile asp pro ile ser ala phe ala gly gln 185 190 leu glu met leu leu pro arg his ser thr tyr his 195 200 ile asp asp met arg leu ser ser asp gly lys gln 205 210 215 ile ile ile thr ala thr met met gly thr ala thr 220 225 asn pro lys glu phe val met asn pro ala asn ala 230 235 240 gln gly arg his thr pro gly thr arg leu 245 250 molecular weight 27574 . 42 daltons 248 amino acids 33 strongly basic (+) amino acids ( k , r ) 21 strongly acidic (−) amino acids ( d , e ) 76 hydrophobic amino acids ( a , i , l , f , w , v ) 80 polar amino acids ( n , c , q , s , t , y ) 9 . 636 isoelectric point 12 . 379 charge at ph 7 . 0 c3 has been reported to be stably expressed in e . coli by both pgex - series and pet - series vectors ( e . g ., dillon and feig , 1995 meth . enzymol . 256 : 174 - 184 . small gtpases and their regulators . part b . rho family . w . e . balch , c . j . der , and a . hall , eds . ; lehmann et al ., 1999 supra ; han et al ., 2001 . j . mol . biol . 395 : 95 - 107 ). the fusion proteins were expressed well in the pgex vector , for synthesis and testing . however , for large - scale production it is more efficient to synthesize recombinant proteins without an affinity tag that increases the size of the protein produced . also , it is more economical to synthesize proteins in large scale by affinity chromatography using automated fplc systems . the polymerase chain reaction was used to transfer recombinant construct c3aplt into the pet t7 polymerase based system e . coli expression system ( reviewed by studier et al ., 1990 . meth . enzymol . 185 : 60 - 89 . gene expression technology . d . v . goeddel , ed .). a similar pcr approach is suitable for others in the fusion protein series of c3 - based constructs with transport sequences . the pet3a vector dna was obtained from dr . jerry pelletier , mcgill university . pcr primers were obtained from invitrogen . the upper ( 5 ′) primer was 5 ′- gga tct ggt tcc gcg tca tat gtc tag agt cga cct g - 3 ( 37 b ) ( seq id no . : 38 ). underlined is the nde i site that was introduced into the primer to replace the bamhi site in pgex4t - c3aplt . the lower primer was 5 ′- cgc gga tcc att agt tct cct tct tcc act tc - 3 ′ ( 32 b ) ( seq id no . : 39 ). this primer introduced two changes in the coding strand dna of pgex4t - c3aplt , replacing the ecori site from pgex4t - c3aplt with a bamih i site ( underlined ) and replacing a tga stop codon with the strong stop sequence taat ( the italicized atta sequence in the complementary primer ). compared to pgex4t - c3aplt , the predicted n - terminal sequence of pet3a - c3aplt is met - ser rather than gly - ser - ser , a loss of one serine and a substitution of met for gly . there were no changes in amino acid sequence at the c - terminus of c3aplt . the target c3aplt gene was amplified using pfu polymerase ( invitrogen / canadian life technologies ) with buffer , dna and deoxyribonucleotide concentrations recommended by the manufacturer . the pcr was carried out as follows : 95 ° c . for 5 minutes , 10 cycles of 94 ° c . for 2 minutes followed by 56 ° c . for 2 minutes then extension at 70 ° c . for 2 minutes , then 30 cycles of 94 ° c . for 2 minutes followed by 70 ° c . completed reactions were stored at 4 ° c . the qiaexii kit ( qiagen ) was used to purify the agarose gel slice containing dna band . the purified pcr product dna and the vector were digested with bamh i and nde i ( both obtained from new england biolabs ) following the instructions of the manufacturer . the digestion products were separated from extraneous dna by agarose gel electrophoresis and purified with the qiaexii kit . the insert and vector dna were incubated together overnight at 16 ° c . with t4 dna ligase according to directions provided by the manufacturer ( new england biolabs ). competent e . coli ( dh5 . alpha ., obtained from invitrogen / canadian life technologies ) were transformed with the ligation mixture . dna was prepared from purified colonies using the qiagen plasmid midi kit , and the entire insert and junction sequences were verified by double strand sequencing of the full length of the clone ( bios & amp ; t , montreal , quebec ) with forward primer 5 ′ aaa tta ata cga ctc act ata ggg 3 ′ ( 24 bases ) ( seq id no . : 40 ) and reverse t7 terminator sequencing primer 5 ′ gct agt tat tgc tcagcg g 3 ′ ( 19 bases ) ( seq id no . : 41 ). the sequence of the c3aplt cdna in pet is given in seq id no . : 42 . the amino acid sequence is given in seq . id no . : 43 . any of sequences given in examples 1 , 2 , 8 , 9 , 10 , 11 , 12 and 13 , 15 and 16 could be modified to retain c3 enzymatic activity and effective transport sequences . for example amino acids encoded from dna at the 3 ′ end of the sequence that represents the translation of the restriction sites used in cloning may be removed without affecting activity . some of the amino terminal amino acids may also be removed without affecting activity . the minimal amount of sequence needed for biological activity of the c3 portion of the fusion protein is not known but could be easily determined by known techniques . for example , increasingly more of the 5 ′ end of the cdna encoding c3 could be removed , and the resulting proteins made and tested for biological activity . similarly , increasing amounts of the 3 ′ end could be removed and the fragments tested for biological activity . next , fragments testing the central region could be tested for retention of c3 activity . therefore , the c3 portion of the protein could be truncated to include just the amino acids needed for activity . alternatively mutations could be made in the coding regions of c3 , and the resulting proteins tested for activity . the transport sequences could be modified to add or remove one or more amino acids or to completely change the transport peptide , but retain the transport characteristics in terms of effective dose compared to c3 in our tissue culture bioassay ( example 4 ). new transport sequences could be tested for biological activity to improve the efficiency of c3 activity by plating neurons and testing them on inhibitory substrates , as described in example 4 . as discussed previously , it has been determined in tissue culture studies , that the minimum amount of c3 that can be used to induce growth on inhibitory substrates is 25 ug / ml ( lehmann , et al . ( 1999 ) j . neurosci . 19 : 7537 - 7547 ; morii , n and narumiya , s . ( 1995 ) methods in enzymology , vol 256 part b , pg . 196 - 206 . if the cells are not triturated , even this dose is ineffective ( fig1 ). in the context of the present invention it has been determined , for example , that at least 40 □ g ( 40 microgram ) of c3 / 20 g mouse needs to be applied to injured mouse spinal cord or rat optic nerve ( mckerracher , canadian patent application no . : 2 , 325 , 842 ). calculating doses that would be required to treat an adult human on an equivalent dose per weight scale up used for rat and mice experiments , it would be necessary to apply 120 mg / kg of c3 ( i . e . alone ) to the injured human spinal cord . this large amount of recombinant c3 protein needed , creates significant problems for manufacturing , due to the large - scale protein purification and cost . it also limits the dose ranging that can be tested because of the large amount of protein needed for minimal effective doses . fusion proteins of the present invention are much more effective than c3 ( i . e ., alone ) in promoting neurite outgrowth on myelin substrate . for example , concentrations of c3aplt and c3aps , 10 , 000 and 1 , 000 times less than the concentration needed for c3 may be used with comparable ( similar ) effects without exhibiting toxic effects ( e . g ., on pc - 12 cells ). c3 - tl and c3 - ts are also able to promote neurite growth on myelin substrates at doses significantly less than c3 . in vivo results also indicate that lower dose of the fusion proteins may be required to promote regeneration and functional recovery after spinal cord injury in mice . thus , fusion proteins of the present invention represent a significant improvement and advantage over c3 in both manufacture cost and doses required for treatment . the formation of new blood vessels can be studied in a cell culture model by growing endothelial cells in the presence of a matrix of basement membrane ( matigel ). human umbilical vein endothelial cells ( huvec ) are harvested from stock cultures by trypinization , and are resuspended in growth medial consisting of ebm - 2 ( clonetics ), fbs , hydrocortisone , hfgf , vegf , r3 - igf - 1 , ascorbic acid , hegf , ga - 1000 , heparin . matrigel ( 12 . 5 mg / ml ) is thawed at 4 ° c ., and 50 ml of matrigel is added to each well of a 96 well plate , and allowed to solidify for 10 min . at 37 ° c . cells in growth medium at a concentration of 15 , 000 cells / well are added to each well , and are allowed to adhere for 6 hours . a fusion protein of this invention , e . g ., c3aplt , in phosphate buffered saline ( pbs ) is added to the well at about 10 mg / ml , and in other wells pbs is added as control . the cultures are allowed to grow for a further 6 to 8 hours . the growth of tubes can be visualized by microscopy at a magnification of 50 ×, and the mean length of the capillary network is quantified using northern eclipse software . treatment of the cells in the matrigel assay with a fusion protein of this invention ( e . g ., c3aplt ) reduces tube formation ( see fig1 ). a solution comprising a unit dosage amount of a composition of this invention comprising a fusion protein such as c3aplt dissolved in an pharmaceutically acceptable isotonic aqueous medium comprising a pharmaceutically acceptable buffer salt and / or a readily water - soluble pharmaceutically acceptable carbohydrate ( preferably a pharmaceutically acceptable non - reducting sugar or a cyclodextrin ) is sterile - filtered ( e . g . through a 0 . 2 micron filter ) under aseptic conditions , the filtrate is placed in a sterilized vial , the filtrate is frozen , the frozen aqueous solution is lyophilized aseptically at reduced pressure in a pharmaceutically acceptable lyophilizer to leave a dried matrix comprising the fusion protein in the vial , the vial is returned to atmospheric pressure under a sterile inert atmosphere , the vial is sealed with a sterile stopper ( e . g . together with a crimp cap ). the sealed vial is labeled with its contents and dosage amount and placed in a kit together with a second sealed sterile vial which contains sterilized water for injection in an amount useful to transfer into the first vial containing the lyophilized fusion protein in order to reconstitute the fusion protein matrix to a solution as a unit dosage form . in another embodiment , the fusion protein can be dissolved in a starting volume of aqueous medium which comprises a hypertonic aqueous medium , the solution sterile filtered , the filtrate filled into a vial , and lyophilized to form a dried matrix . this dried matrix can be dissolved or reconstituted in a larger - than - original volume of sterile water , the larger volume sufficient to form an isotonic solution for injection such as by intravenous injection and / or infusion . alternatively , a hypertonic solution can be used for administration by infusion into a drip bag containing a larger volume of isotonic aqueous medium such that the hypertonic solution is substantially diluted . optionally , a vial containing a volume of sterile water in an amount suitable to reconstitute the matrix to a unit dosage form is distributed as a kit with the lyophilized protein . preferably the reconstituted composition comprises an isotonic solution . the fusion protein can be used for intravenous delivery , and / or infusion , and / or direct injection into tissue of the eye or tissue proximal to the eye with this formulation . c3 - 07 is a derivative of c3aplt lacking the gst sequence . c3 - 07 was prepared by polymerase chain reaction and subcloned into pet9a vector to create c3 - 07 . c3 - 07 differs from c3 - 05 by silent amino acid changes which can be described as a deletion of the terminal glycine in c3 - 05 which provides a truncated fragment of c3 - 05 terminating in a serine plus a mutation ( i . e ., substitution ) of that terminal serine in the truncated fragment by a methione to provide c3 - 07 . c3 - 07q189a was made by intentionally producing a mutation in c3 - 07 near the adp - ribosyl transferase catalytic site in the fusion protein , thereby substantially reducing adp - ribosylation activity . two oligonucleotides were designed to change the amino acid 189 glutamine at the active site ( gln , q , coded by caa ) to 189 alanine ( ala , a , coded by gca ) by site - directed - mutagenesis using the quikchange ( stratagene ). polymerase chain reaction was carried out in a thermo cycler using 50 ng of “ pet9a - ba - 207 ” which is sometimes also referred to as “ pet9a - ba05 ”, 133 ng of 41 - mer mutant primer zsm3 , and 137 ng of 41 - mer mutant primer zsm4 . the cycle program for the q189a mutant was as follows : 95 ° c . for 30 sec , 18 cycles of 95 ° c . for 30 sec ., 55 ° c . for 1 min ., and 68 ° c . for 10 min ., and hold at 4 ° c . primer zsm3 5 ′- gct ttt gca gga { gc } a ctt gaa atg ttg ctt cct aga cat ag ′ primer zsm4 5 ′- ct atg t ct a gg aag caa cat ttc aag t { gc } tcc tgc aaa agc - 3 ′ the bracketed bold letters in the above sequence denote the change from the c3 - 07 sequence . the amino acid sequence of c3 - 07 is seq id no . : 43 . dpni digestion was done according to the manufacturer &# 39 ; s instructions and 1 μl of this product was used to transform xl1 - blue competent cells . these plates were then incubated overnight at 37 ° c . clones of putative c3 - 07q189a were selected and their plasmid dna amplified and purified using the qiagen midi kit . the purified plasmids were analyzed by restriction digestion analyses . the dna from three candidate clones was sequenced at bios & amp ; t ( lachine , quebec ) using the t7 and t7t primers . mutant zsmt2 - 2 was confirmed to contain the mutation and the dna was used to transform bl21 ( de3 ) cells and prepare a research cell bank ( rcb ). purified c3 - 07q189a was prepared from e . coli . first , a flask of 0 . 5 l luria broth with glucose was inoculated with 2 vials of research cell bank ( rcb ) of pet9a - c3 - 07q189a and grown overnight . the starter culture was diluted 10 - fold into 8 flasks each containing 500 ml growth medium . the flasks were incubated at 37 ° c . and after 1 hour 20 min , isopropylthio - b - d - galactoside ( iptg ) was added to increase the expression of c3 - 07q189a . after a further 4 hours , the cells were harvested by centrifugation and stored at − 80 ° c . until required . a sample of the harvested culture was analyzed for c3 - 07q189a content . next , the cells were thawed and subjected to primary recovery , which in the research scale process for production of c3 - 07 is sonication in extraction buffer . the crude extract was treated with positively - charged polymer to remove nucleic acids and with ammonium sulfate to remove some proteins and reduce the volume . excess salt was removed . the protein was further purified by passing over four chromatography columns . the final purification and isolation steps consisted of concentration of the resulting purified protein solution ( ultrafiltration can be used ), filtration of the protein solution ( e . g ., through a 0 . 2 micrometer filtration membrane which can be useful to sterilize the protein solution ), dispensing of the solution into sterile tubes , freezing the protein solution , and lyophilization of the frozen solution to leaving the protein formulated in the form of a powder . after the c3 - 07q189a was purified , the fusion protein was analyzed to determine the amount of protein which was produced , its purity , its potency and its biological activity ( e . g ., adp - ribosyl transferase related activity for neurite outgrowth ). purity was measured by scanning densitometry of sds - polyacrylamide gels stained with coomassie blue . the activity of c3 - 07q189a was determined using an ng108 cell 4 hour neurite outgrowth bioassay . the procedure for the bioassay comprises incubation of h ng - 108 cells for 4 hours with an aliquot of a buffered solution containing c3 - 07q189a . a simultaneous and otherwise identical bioassay was run as a positive control , wherein c3aplt or c3 - 07 was used in place of c3 - 07q189a . the cells were then fixed with paraformaldehyde , stained with cresyl violet , and the percentage of cells in each well that demonstrated neurites greater than one cell body in length was determined by counting under the microscope . each data point was determined in triplicate . met ser arg val asp leu gln ala cys asn ala tyr ser ile asn 1 5 10 15 gln lys ala tyr ser asn thr tyr gln glu phe thr asn ile asp 20 25 30 gln ala lys ala trp gly asn ala gln tyr lys lys tyr gly leu 35 40 45 ser lys ser glu lys glu ala ile val ser tyr thr lys ser ala 50 55 60 ser glu ile asn gly lys leu arg gln asn lys gly val ile asn 65 70 75 gly phe pro ser asn leu ile lys gln val glu leu leu asp lys 80 85 90 ser phe asn lys met lys thr pro glu asn ile met leu phe arg 95 100 105 gly asp asp pro ala tyr leu gly thr glu phe gln asn thr leu 110 115 120 leu asn ser asn gly thr ile asn lys thr ala phe glu lys ala 125 130 135 lys ala lys phe leu asn lys asp arg leu glu tyr gly tyr ile 140 145 150 ser thr ser leu met asn val ser gln phe ala gly arg pro ile 155 160 165 ile thr gln phe lys val ala lys gly ser lys ala gly tyr ile 170 175 180 asp pro ile ser ala phe gln gly ala leu glu met leu leu pro 185 190 195 arg his ser thr tyr his ile asp asp met arg leu ser ser asp 200 205 210 gly lys gln ile ile ile thr ala thr met met gly thr ala ile 215 220 225 asn pro lys glu phe val met asn pro ala asn ala gln gly arg 230 235 240 his thr pro gly thr arg leu 245 atgtctagag tcgacctgca ggcatgcaat gcttattcca ttaatcaaaa ggcttattca 60 aatacttacc aggagtttac taatattgat caagcaaaag cttggggtaa tgctcagtat 120 aaaaagtatg gactaagcaa atcagaaaaa gaagctatag tatcatatac taaaagcgct 180 agtgaaataa atggaaagct aagacaaaat aagggagtta tcaatggatt tccttcaaat 240 ttaataaaac aagttgaact tttagataaa tcttttaata aaatgaagac ccctgaaaat 300 attatgttat ttagaggcga cgaccctgct tatttaggaa cagaatttca aaacactctt 360 cttaattcaa atggtacaat taataaaacg gcttttgaaa aggctaaagc taagttttta 420 aataaagata gacttgaata tggatatatt agtacttcat taatgaatgt ttctcaattt 480 gcaggaagac caattattac aaaatttaaa gtagcaaaag gctcaaaggc aggatatatt 540 gaccctatta gtgcttttgc aggagcactt gaaatgttgc ttcctagaca tagtacttat 600 catatagacg atatgagatt gtcttctgat ggtaaacaaa taataattac agcaacaatg 660 atgggcacag ctatcaatcc taaagaattc gtgatgaatc ccgcaaacgc gcaaggcaga 720 catacacccg gtaccagact ctag 744 general procedure to determine the relative neuroprotection ability in the retina of a fusion protein of this invention c3 - aplt and c3 - 07 are examples of fusion proteins of this invention , each protein having adp - riboysyl transferase activity and each having an adp - riboysyl transferase active site . in the visual system , retinal ganglion cells die after optic nerve injury . the severity ( i . e ., the number of cells which die ) and rate of cell death depends on the proximity of axonal injury to the eye . to study the effects of inactivation of rho on rgc survival we have made use of two cell - membrane penetrating ( i . e ., cell - membrane permeable ) derivatives of c3 transferase : c3 - aplt and c3 - 07 . rats were anaesthetised under 2 - 3 % isoflurane . rgcs were retrogradely labelled from the superior colliculus with fluorogold ( fluorchrome inc , denver , co .). the right midbrain of a rat was exposed by making a small circular opening in the bone , followed by aspiration of cortex , and removal of the pia matter overlying the superior colliculi . a small piece of gelfoam soaked in an aqueous medium comprising 2 % fluorgold and 10 % dmso was applied to the surface of the right superior superior colliculus . seven days after fluorogold application , the left optic nerve was transected 1 mm from the eye . the optic nerve was accessed within the orbit by making an incision parasagitally in the skin covering the superior rim of the orbit bone , taking care to leave the supraorbital vein intact . following partial resection or reflection of the lacrimal gland , the superior extraocular muscles were spread with a small retractor or 6 - 0 silk suture . the optic nerve was exposed , and the surrounding sheath was cut longitudinally to avoid cutting blood vessels while exposing the optic nerve . the pia mater of the optic nerve was nicked , the optic nerve moved gently to dislodge it , and then scissors were slipped tangentially under the optic nerve to give a clean cut 1 mm from . the eye . in animals used for studies on cytokine levels , a microcrush lesion was used . for these studies the pia was left intact , and the optic nerve was lifted out from the sheath and crushed 1 mm from the globe by constriction with a 10 . 0 suture held for 60 seconds . anesthetised animals received single injections of c3aplt or c3 - 07 in aqueous buffer immediately after the optic nerve was cut , or 4 days later . intraocular injections were made with a 10 μl syringe attached to a glass micropipette . a hole was made in the superior nasal retina approximately 4 mm from the optic disc with a 30 g needle before introduction of the glass pipette to inject 5 μl of fusion protein ( e . g ., c3 - 07 ) or buffer control . the needle was withdrawn slowly to allow diffusion of the solution into the vitreous spaces . the sclera was then sealed with tissue adhesive ( indermil , tyco heathcare , mansfield , usa ). care was taken not to damage the lens during injection to avoid cataract formation and consequential increased survival of the rgcs . the skin was closed , and the integrity of the retinal vasculature was evaluated by a postoperative ophthalmoscopic examination . rats with compromised vasculature or rats that developed cataracts were not included in the experimental results . fluorogold labeled retinas were prepared for counting 7 or 14 days after axotomy . animals were perfused with 4 % paraformaldehyde ( pfa ), and their eyes were removed and postfixed in 4 % pfa after puncture of the cornea . the eyes were then rinsed with phosphate buffered saline ( pbs ) for 1 hour . incisions were made in each eye in the four retinal quadrants , and the retinas were removed and flat - mounted on glass slides . excess vitreous was blotted away with paper wicks . coverslips were placed on the slides over the mounted retinas , and rgcs were examined with an ultraviolet filter ( 365 / 420 ). labeled rgcs were counted under the microscope at 20 × magnification with the aid of a rectangle insert in one ocular field of view of the microscope to provide a rectangular field area of 0 . 375 mm × 0 . 1125 mm . four standard rectangular areas of retina were counted at 1 and 2 mm from the disc . the number of labeled cells in each area was divided by 0 . 04125 ( rectangular area counted in mm 2 ), and the average density for each retina was calculated as rgcs / mm 2 . cells counts were conducted by the same investigator blind to the treatment . after axotomy , fluorogold is also present in endothelial cells and microglial cells . these cells , identified by morphology were excluded from the counts of rgcs . statistics were performed with excel , and results from treated animals were compared with results from controls by t - test . a single injection of fplc - purified c3aplt was neuroprotective and rescued all rgcs at 7 days after axotomy , and a single injection of fplc - purified c3 - 07 was neuroprotective and rescued all rgcs at 7 days after axotomy . to determine if rgc cell survival following c3 - 07 injection might be increased because of properties of c3 - 07 other than its rho ribosylation activity , we tested the effect of c3 - 07q189a on rgc cell survival . the mutant - protein , c3 - 07q189a , was purified by fplc , and 1 ug was injected immediately after axotomy in the manner used for c3 - 07 . cell survival following administration of c3 - 07q189a was not significantly different from cell survival following axotomy alone , and was significantly different from the effect of c3 - 07 ( fig1 ). therefore , the neuroprotective activity of c3 - 07 is due to the presence of adp - ribosyl transferase in the fusion protein and thus inactivation of rho , not from other effects . ischemia can be produced in the retina of the albino lewis rat by raising intraocular pressure by intraocular injection of saline ( unoki and lavail , invest opthalmol vis . sci . 35 : 907 , 1994 ). the survival of rgcs can be assessed by counting rgcs retrogradely labeled with florogold in retinal wholemounts , as described above . procedure to measure efficacy to prevent photoreceptor cell death in rat models of photoreceptor degeneration the rescue of photoreceptor cells can be demonstrated in royal college of surgeons ( rcs ) rats , which rats have an inherited retinal degeneration ( faktorovich et al ., nature 347 : 83 , 1990 ). intraocular injections of c3aplt in aqueous buffer are made with a 10 μl syringe attached to a glass micropipette . a hole is made in the superior nasal retina approximately 4 mm from the optic disc using a 30 g needle before introduction of the glass pipette to inject 5 μl of 1 ug c3 - aplt or buffer control . the needle is withdrawn slowly to allow diffusion of the solution into the vitreous spaces , and the sclera is sealed with tissue adhesive . care is taken not to damage the lens during injection because lens damage can lead to cataract formation and consequent increases in survival of the rgcs . the skin is closed , and the integrity of the retinal vasculature is evaluated by a postoperative ophthalmoscopic examination . rats with compromised vasculature or rats that develop cataracts are not included in the experimental results . a histological analysis useful to assess photoreceptor survival in therapeutically treated or untreated rcs rats comprises the steps of vascular perfusion of an anesthetized animal , embedding of the animal &# 39 ; s eye in paraffin , and staining of 6 micron thick sections with hemotoxyline and eosin or with toluidine blue . in the eyes of untreated rcs rats at 53 days after birth ( p53 ) the outer nuclear layer , which contains the photoreceptor cells , is reduced in thickness to only a few . rows of cells ( approximately 20 % of the thickness found in normal rats at the same age ). a therapeutically effective dose of c3aplt administered by intravitreal administration ( e . g ., a single injection comprising one microgram of protein ) can restore the thickness of the outer nuclear layer , and hence rescue photoreceptor cells . alternatively , rescue of photoreceptor cells can be demonstrated using 2 - to - 3 month old male sprague - dawley rats in a model of exposure to constant light ( 115 - 200 foot - candles ) for 1 week following the procedures of lavail et al ., pnas usa 89 : 11249 , 1992 , the disclosure of which is incorporated herein by reference . an aqueous buffer solution of c3aplt can be injected ( 1 ug of protein ) into the subretinal space or into the vitreous humor 48 hours prior to the onset of continuous illumination . histological examination and analysis of retinas following a fixed recovery period ( usually 10 days ) is used to assess the death or damage to and the rescue or survival of photoreceptor cells . retinal detachment also leads to the death of photoreceptor cells . an animal model described by erickson et al ., j struct . biol . 108 : 148 , 1992 , the disclosure of which is incorporated herein by reference , can demonstrate the effect of administration of c3aplt to enhance survival of retinal cells in vitro relative to administration of buffer control , a protein mutated to eliminate adp - ribosylation activity , and to untreated controls . procedure to measure efficacy of a fusion protein of the invention to prevent photoreceptor cell death in transgenic mouse models of photoreceptor degeneration several mouse genetic models of photoreceptor degeneration ( e . g ., rd - mutant of b subunit of cgmp phosphodiesterasel rds - mutant of peripherin ) can be employed using the modes of administration described above to demonstrate fusion protein - related ( e . g ., c3aplt - related ) photoreceptor cell enhanced survival effects in vivo . rd - mutant mice and rds - mutant mice exhibit retinal degeneration within a few weeks after birth . following intravitreal injection of a fusion protein ( e . g ., c3aplt ) as described above , tissues are analysed by histological methods described above . retinal explants from rd - mutant mice cultured in a c3aplt - containing medium can be assayed for thickness of the outer nuclear layer using methods described in caffe et al ., curr . eye res . 12 : 719 , 1993 , the disclosure of which is hereby incorporated by reference . thus , mouse pups are enucleated 48 hours after birth and treated with proteinase k . after this enzyme treatment , the neural retina with the retinal pigmented epithelium ( rpe ) attached is recovered , placed into a multi - well culture dish , and incubated in 1 . 2 ml culture medium ( e . g ., r16 ) for up to 4 weeks at 37 ° c . with 5 % co2 . immunocytochemical staining for opsin of fixed ( e . g ., 4 % paraformaldehyde ) sections is used to assess the degeneration and rescue of photoreceptor cells . in the rd - mutant mouse the outer nuclear layer ( photoreceptor cells ) degenerate after 2 - to - 4 weeks in culture . the media can be supplemented with a dose range of c3aplt to achieve an effect on retinal cell function , such as rescue of the outer nuclear layer from degeneration . survival effects can also be shown using the tunel method on sections of retina analysed in the models described above . procedure to determine efficacy of a fusion protein to prevent neovascularization of the retina uncontrolled retinal angiogenesis can contribute to the pathology of a number of diseases of the retina such as wet macular degeneration , retinitis pigmentosa , stargardt &# 39 ; s disease , diabetic retinopathy , hypertensive retinopathy , and occlusive retinopathy . vascular endothelial growth factor ( vegf ) production is increased by hypoxia in the retina , and neovascularization of the retina is thereby induced . a mouse model of ischemia - induced retinal neovascularization employs newborn c57bl / 6j mice which are exposed to 75 % o2 from postnatal day ( p ) 7 to p12 , along with their nursing mothers , followed by a return to room air . to accomplish this , the mice are weighed and placed at day p7 in a plexiglass box which serves as an oxygen chamber together with enough food and water for 5 days to p12 . an oxygen flow rate of 1 . 5 l / min is maintained through the box for 5 days . the flow rate is checked twice daily with a beckman oxygen analyzer ( model d2 , irvine calif .). the chamber is not opened during the 5 days of hyperoxia . an intraocular injection of a fusion protein ( e . g ., c3aplt ) is performed at day p12 and the mice are removed to ambient air thereby inducing hypoxia . at day p17 the mice are sacrificed by cardiac perfusion with saline followed by 4 % paraformaldehyde ( pf ), and their eyes are removed and fixed in pf overnight . the eyes are then rinsed , brought through a graded alchohol series , and then radial sections 6 um thick are cut . sections through the optic nerve head are stained with periodic acid / schiff reagent and hematoxylin . sections 30 um apart are evaluated for a span of 300 um through the retina . all retinal vascular nuclei anterior to the internal limiting membrane are counted in each section . the mean of 10 counted sections is determined to give the average number of neovascular nuclei per section per eye . no vascular cell nuclei anterior to the limiting membrane are observed in normal , unmanipulated animals . the administration of a fusion protein substantially reduces the number of retinal vascular nuclei relative to the number observed in the absence of fusion protein .
the rho family gtpases regulates axon growth and regeneration . inactivation of rho with c3 , a toxin from clostridium botulinum , can stimulate regeneration and sprouting of injured axons . the present invention provides novel chimeric c3 - like rho antagonists . these new antagonists are a significant improvement over c3 compounds because they are 3 - 4 orders of magnitude more potent to stimulate axon growth on inhibitory substrates than recombinant c3 . the invention further provides evidence that these compounds promote repair when applied to the injured mammalian central nervous system .